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Abstract
The E2F1 transcription factor transcribes the genes necessary for S phase progression and induces 
apoptosis when activated by DNA damage. Therefore, E2F1 has an interesting dual role, acting as a 
classical proto-oncogene or tumor suppressor depending on the cellular context. What remains unknown 
is the contribution of pRB regulation of E2F1 to E2F1-dependent apoptosis in response to DNA damage. 
I have studied the regulation of pRB and E2F1 interactions by DNA damage-responsive post- 
translational modifications in order to characterize the functional role of pRB/E2Fl complexes in 
response to genotoxic stress. I report that DNA damage directs the formation of distinctly modified 
pRB/E2Fl complexes. I characterize the post-translational modifications and functional role of two 
pRB/E2Fl complexes. Following DNA damage, acetylated E2F1 and pRB comprise a pRB/E2Fl 
complex that includes primarily hypophosphorylated pRB and CHK2 phosphorylated E2F1 forms a 
transcriptionally active, proapoptotic complex with hyperphosphorylated pRB that excludes other post- 
translational modifications.
Keywords: E2F1, pRB, post-translational modification, apoptosis, DNA damage, protein complex, 
phosphorylation, acetylation, immunoprécipitation, endogenous, proapoptotic pRB, cancer.
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1.1 pRB controls the decision for cells to enter S-phase
1.1.1 pRB inhibits S phase entry by blocking E2F activity - a mechanism o f tumor suppression 
The retinoblastoma tumor suppressor protein (pRB) was identified as the gene product of
the retinoblastoma susceptibility gene RBI which, when mutated, results in the development of 
an inherited cancer characterized by multifocal tumors in the retina termed retinoblastoma (Lee 
et al. 1987, Friend et al. 1986). pRB was classified as a tumor suppressor protein long before its 
function or mechanism of tumor suppression was understood (Whyte et al. 1988). Over the last 
two decades rigorous investigation into pRB’s function has revealed its major role as a cellular 
gatekeeper- to control the proper entry from G1 into S-phase of the cell cycle by regulating the 
activity of the E2F family of transcription factors which transcribe the genes necessary for S- 
phase progression (DeCaprio et al. 1989, Chellappan et al. 1991, Hiebert et al. 1992, reviewed in 
Dyson, N 1998). pRB is a large (1 lOkD) nuclear phosphoprotein (Lee et al. 1987) that contains 
multiple binding clefts. pRB interacts with E2Fs through a binding cleft in its “pocket domain” 
which consists of two cyclin folds and the pRB c-terminus (Lee et al. 1998) (Figure 1.1). The 
highly related proteins pl07 and pl30 join pRB to complete the pocket protein family that bind 
E2Fs and have major roles in cell cycle regulation. Unlike pRB, however, pl07 and pl30 do not 
seem to have a critical role in tumor suppression (Classon and Dyson, 2001 and Mulligan and 
Jacks, 1998). pRB has no intrinsic DNA binding activity of its own but rather acts as a 
transcriptional repressor by binding to E2Fs on cell cycle promoters and masking the E2F 
transactivation domain (Helin et al. 1993, Lee et al. 2002). pRB can repress E2F targets in a 
more permanent way by recruiting chromatin modifying enzymes such as histone deacetylases 
and histone methyltransferases to add repressive chromatin marks at E2F-responsive promoters
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Figure 1.1. pRB interaction with E2Fs.
The gene product of the retinoblastoma susceptibility gene RBI (pRB) interacts with E2Fs through a 
binding cleft in its “pocket domain” consisting of the A and B portions of the pocket along with the 
pRB C-terminus. E2Fs interact with pRB through a binding site in their C-terminal transactivation 
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(Nielsen et al. 2001, Robertson et al. 2000, Brehm et al. 1998, Magnaghi et al. 1998). In this way 
it is the activity of pRB that regulates the expression of E2F target genes required for entry into 
S-phase and so pRB activity is tightly regulated in a cell cycle dependent manner to prevent 
premature DNA replication.
1.1.2 Phosphorylation control o f pRB/E2F interactions in cycling cells
The activity of pRB is controlled in a cell cycle dependent manner by extensive 
phosphorylation along its length by cyclin/CDK complexes (DeCaprio et al. 1992, Lin et al. 
1991). pRB is typically described as existing in one of two states; hypophosphorylated and active 
or hyperphosphorylated and inactive. This convention exists as when pRB is not phosphorylated 
(hypo-pRB) it forms interactions with E2Fs, viral oncoprotein and chromatin modifying enzymes 
but these interactions are lost when pRB becomes phosphorylated (hyper-ppRB), resulting in 
“inactive” pRB because it is deficient for interaction with its normal binding partners (Knudsen 
and Wang 1996 and 1997, Ludlow et al. 1989, Takaki et al. 2004). During the GO phase of the 
cell cycle pRB is in its hypophosphorylated, or active, state and binds E2Fs to form an inhibitory 
complex (Chen et al. 1989, Hinds et al. 1992). However, upon mitogenic stimulation the activity 
of the G1 cyclin dependent kinases (CDK’s) increase and pRB becomes extensively 
phosphorylated by cyclinD-CDK4/6 and cyclinE-CDK2 ,which converts pRB to its 
hyperphosphorylated, inactive state, accompanied by a conformational change which renders it 
unable to bind and inhibit E2Fs (Rubin et al. 2005, Burke et al. 2010). The release of pRB’s 
inhibition on E2Fs allows the expression of genes required for S-phase progression and DNA 
synthesis such as cyclin A, DNA pola, thymidylate synthase, thymidylate kinase and 
dihydrofolate reductase (Black et al. 2005, Muller et al. 2001) (Figure 1.2).
6
Figure 1.2. pRB regulation of E2F transcription factors.
Hypophosphorylated, active pRB binds to E2F-DP1 heterodimers on the DNA, blocks the E2F 
transactivation domain and recruits repressive chromatin modifying enzymes thereby preventing 
transactivation of E2F responsive promoters. Upon mitogenic signaling, G1 cyclin/CDK complexes are 
activated and phosphorylate pRB, converting it to the hyperphosphorylated and inactive form. E2F is 
relieved of pRB binding and activates expression of the genes required for S-phase progression.
7
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1.2 The Function of the E2F family of transcription factors
1.2.1 Activator E2Fs
The E2F family of transcription factors contains 8 identified members (E2F1-E2F8) with 
which E2F1, E2F2 and E2F3 are considered “activator” E2Fs (Figure 1.3). Activator E2Fs have 
high sequence homology, exhibit functional redundancy, and share a highly conserved basic 
helix-loop-helix DNA binding domain adjacent to a hydrophobic heptad repeat leucine zipper 
(Zheng et al. 1999). These domains are necessary and sufficient to bind directly to DNA and 
activate transcription at promoters that contain the “TTTc/gGCGCc/g” E2F response element 
(Tao et al. 1997). The activator E2Fs form constitutive heterodimers with the structurally related 
DP proteins through similar dimerization domains and the interaction between E2F and DP is 
necessary to form high affinity E2F-DNA complexes (Bandara et al. 1993, Helin et al. 1993, 
Cress et al. 1994). The overexpression of activator E2Fs leads quiescent cells to enter S phase 
(Johnson et al. 1993) and until very recently it was thought that the expression of activator E2Fs 
was necessary for cell proliferation (Chen et al. 2009, Wenzel et al. 2010). E2Fs are themselves 
E2F target genes and transcriptional activation by activator E2Fs is regulated by the inhibitory 
binding of pRB. Due to this regulation, activator E2Fs are expressed in a cell cycle dependent 
manner, peaking late in G1 coincident with the inhibition of pRB and declining after the onset of 
S phase due to the activity of “repressor” E2Fs (Harbour et al. 1999, Leone et al. 1998, Di 
Stefano et al. 2003, Christensen et al. 2005).
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Figure 1.3. The E2F family of transcription factors.
The E2F family is composed of 8 members classified as activators or repressors. E2F activators 
possess a nuclear localization signal while repressors do not. E2F1-6 contain a dimerization and 
marked box domain which facilitates the binding of DP subunits, which allows for high affinity 
E2F-DNA binding. Activator E2F’s bind and are repressed by pRB while the repressor E2F’s 
predominantly bind to the other pocket protein members, p i07 and p i30. E2F6-8 repress E2F 
target genes independently of pocket proteins. E2F7 and E2F8 do not dimerize with DP proteins 
and instead can form homodimers or heterodimers with one another. NLS= nuclear localization 
signal, CycA= cyclin A binding domain, DBD= DNA binding domain, DMZ= dimerization 
domain, MB= marked box domain, TA= transactivation domain, RB= RB binding domain. 


















E2F4-E2F8 share common transcriptional targets with E2F1-3 but are classified as 
repressors and lack a nuclear localization signal, unlike their activating counterparts (Figure 1.3). 
While the cell cycle related function of activator E2Fs is to induce S phase progression, repressor 
E2Fs act in an opposite way. The activity of E2F4 and E2F5 is highest in non-cycling cells 
where they form inhibitory complexes with pocket proteins at E2F targets in order to maintain 
cells in a quiescent state (Sardet et al. 1995, Litovchick et al. 2007). Conversely, E2F6, E2F7 and 
E2F8 repress E2F target gene expression in G2 upon the completion of S phase in a pocket 
protein independent manner (Zhu et al. 2004, Di Stefano et al. 2003, Christensen et al. 2005). 
E2F6 represses transcription by recruiting the polycomb complex (Trimarchi et al. 2001). E2F7 
and E2F8 are the most nonconforming E2Fs as they lack the necessity to dimerize with a DP 
subunit and instead form homodimers or heterodimers with one another and repress E2F targets 
in G2/M (Di Stefano et al. 2003, Christensen et al. 2005).
Besides their role in regulating proliferation, repressor E2Fs are necessary for cell cycle 
independent functions during development. Complete loss of E2F4 results in maturation defects 
in multiple hematopoietic lineages and the gut epithelium (Rempel et al. 2000). E2F5 has an 
essential role in the proper development and function of the choroid plexus, as loss of E2F5 
results in excessive cerebrospinal fluid production (Lindemen et al. 1998). In cooperation with 
polycomb group proteins 6 and 7, E2F6 is necessary for the long-term somatic silencing of 
certain male-germ-cell-specific genes (Pohlers et al. 2005). Interestingly, E2F7 and E2F8 are 
important to restrict the activity of E2F1 and p53 mediated apoptosis during development, and 
combined loss of E2F7 and E2F8 results in embryonic lethality due to widespread apoptosis (Li
et al. 2008).
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1.2.3 Unique E2F1 properties
While E2F1 is classified as an activator E2F like E2Fs 2 and 3, it has many unique 
functional properties that are not shared by other E2Fs. E2Fl’s primary non cell cycle activity is 
its intricate involvement in a cell’s response to genotoxic stress. E2F1 integrates metabolic 
signals in order to balance proliferative and apoptotic transcription (Hallstrom et al. 2008), is 
activated by DNA double strand breaks as part of the DNA damage responsive signaling 
pathway (Lin et al. 2001, Stevens et al. 2003) and assists in DNA repair (Ren at al. 2002, Chen et 
al. 2011). In many ways E2F1 has overlapping roles with the tumor suppressor protein p53, 
“guardian of the genome”, and for this reason E2F1 is often described to have both oncogenic 
and tumor suppressive properties depending on the cellular context (reviewed in Polager and 
Ginsberg, 2009).
Besides E2Fl’s nontraditional activator E2F functions it also differs from other E2F family 
members in that its interaction with pRB is extremely complex. E2F1 can bind pRB in two 
discrete ways, both inside pRB’s pocket domain and in a more C-terminal E2F1 “specific” 
binding cleft (Dick and Dyson, 2003). Binding of E2F1 to pRB in the C-terminal “specific” cleft 
has been demonstrated to regulate E2F1 activity that is unrelated to proliferation (Julian et al. 
2008). This extra layer of complexity in regulating only pRB and E2F1 interactions highlights 
the fact that E2F1 has unique activity not shared by other E2Fs.
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1.3 E2F1 is a proapoptotic transcription factor
1.3.1 Lessons from the E2fl-/- mouse
While it had been observed that ectopic expression of E2F1 in vitro induced both S phase 
entry and apoptosis (Kowalik et al. 1995), E2F1 ’s role in apoptotic induction was demonstrated 
by the emergence of the E2fl-/- mouse. In 1996 two labs published similar manuscripts 
describing the phenotype of mice null for a single activator E2F; E2F1 (Yamasaki et al. and 
Field et al. 1996). E2fl knockout mice are viable and fertile, but have defects in thymocyte 
negative selection, a normal process during development that eliminates self- antigen detecting 
thymocytes by apoptosis. This defect leads to an increased number of immature T cells, and 
E2fl-/- mice exhibit thymic hypertrophy and often develop thymic lymphoma by 11 months of 
age. While E2fl-/- mice primarily develop thymic lymphoma, these mice also develop 
reproductive tract sarcomas, lung adenocarcinomas and multiple other tumor types (Yamasaki et 
al. 1996). While initially it could be hypothesized that loss of E2fl is oncogenic due to the loss of 
repressive pRB/E2Fl complexes, the spectrum of tumors generated by Rbl loss (Jacks et al.
1992) is not consistent with loss of E2fl, highlighting E2Fl’s role as a proapoptotic tumor 
suppressor during development.
The ability to induce apoptosis is an E2F1-specific function among E2Fs. Redundancy 
among activator E2Fs and the fact that E2Fs are themselves E2F target genes complicated the 
interpretation of activator E2F induced apoptosis. While the ectopic expression of the activator 
E2F3 also results in induction of apoptosis in primary mouse fibroblasts, this effect was shown to 
be lost in the absence of E2F1 (Lazzerini Denchi and Helin, 2005). The mechanism of E2F3 
induced apoptosis is, therefore, activation of E2F1 expression. Accordingly, loss of E2F3 does
14
not result in tumorigenesis in mice (Humbert et al. 2000 and Cloud et al. 2002).
1.3.2 E2F1 induces p53 dependent and p53 independent apoptosis
The E2fl knockout mouse prompted further studies into E2Fl’s robust apoptotic abilities, 
leading to the discovery of E2Fl’s downstream proapoptotic target genes. The mechanism of 
E2F1-induced apoptosis is fairly straightforward-E2Fl can directly transactivate the expression 
of many genes that contain E2F transcription factor binding motifs in their promoters and result 
in mitochondria-dependent apoptosis. E2F1 targets include the cytochrome-C binding protein 
APAF-1, caspases 3 and 7 (the key effectors of apoptosis), TAp73 which is a p53 family member 
and likely E2Fl’s most important apoptotic target, and BH3-only proteins which inactivate Bcl-2 
and activate Bax/Bax-like pro-apoptotic family members (Muller et al. 2001 and Irwin et al. 
2000) (Figure 1.4). Apoptosis elicited by these E2F1 transcriptional targets is independent of p53 
activity, however, the E2F1 and p53 signaling networks also have extensive crosstalk implicating 
E2F1 activity in the apoptotic signaling cascade. While E2F1 can activate expression of many 
genes that activate p53, such as Arf, PIN1, and ASPP1-2, E2F1 can also directly bind 
phosphorylated p53 and increase its overall nuclear retention and fransactivation ability (Phillips 
et al. 1999, Kowalik et al. 1995 and Polager et al. 2009). While the mechanism and signaling 
involved in E2F1-induced apoptosis has been extensively classified, the regulation of E2F1- 
dependent cell cycle versus apoptotic activity remains a central question to the understanding of 
the opposing, bifunctional nature of E2F1.
15
Figure 1.4. E2F1 is activated by the DNA damage response to induce apoptosis in a p53 
dependent and independent manner.
ATM and CHK2 phosphorylate and activate E2F1, which then transactivates the expression of 
proapoptotic target genes, such as TAp73, resulting in mitochondrial dysfunction and apoptosis. 
E2F1 also has extensive crosstalk with p53 in response to DNA damage. E2F1 and p53 share the 
same upstream regulators (ATM, CHK1/2 and PCAF/p300) and transactivate many common 
proapoptotic target genes (shown in red). As well, E2F1 transcribes ARF, which inhibits p53 
degradation in order to induce cell cycle arrest as well as apoptosis.
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1.3.3 A regulatory mechanism to separate E2F1 dependent apoptotic and cell cycle activities?
The specific ability of E2F1 to induce apoptosis is not dependent on its DNA binding 
domain (Hallstrom and Nevins, 2003). Likewise, E2F1 recognizes cell cycle and apoptotic 
transcriptional targets in the same manner, through binding to E2F response elements in target 
promoters. Since cis elements in apoptotic target genes do not seem to differentiate themselves 
from E2F1 ’ s cell cycle targets, one mechanism to explain the proper regulation of E2F1 ’ s 
apoptotic targets is the existence of specific apoptotic coactivator proteins.
E2F1 dependent apoptosis has been mapped to activity governed by the E2F1 marked box 
domain (Hallstrom and Nevins, 2003). As such, a follow up study by the same authors conducted 
a yeast-two-hybrid screen to identify proteins that bind to the E2F1 marked box domain 
(Hallstrom and Nevins, 2006). The authors purified a protein called Jabl, an E2F1 -specific 
binding partner that synergized with E2F1 in apoptotic induction but not cell cycle entry. 
However, Jabl has no DNA binding activity and the presence of Jabl/E2F1 complexes 
specifically at proapoptotic promoters and absent at cell cycle promoters was not demonstrated. 
Synergistic apoptotic activation mediated by E2F1 and Jabl has never been recapitulated or 
elucidated.
E2F1 dependent apoptosis has also been proposed to be regulated by a suppressive 
mechanism while cells are engaging a proliferative program. It was shown that PI3K/Akt 
signaling regulates the balance of E2F1 dependent apoptotic and proliferative transcription by 
specifically blocking the expression of E2F1-responsive apoptotic genes but not proliferative 
genes (Hallstrom et al. 2008). However, the apoptotic targets examined in this study were novel 
and while conclusions could be extrapolated, the regulation of E2Fl’s well characterized 
apoptotic targets such as TAp73 and caspases during normal proliferation was not described.
17
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Similarly, the identification of the hSirtl deacetylase as an E2F1-specific apoptotic co-repressor 
has added to our understanding of the regulation of the E2F1 apoptotic program (Pediconi et al. 
2009). It was shown that hSirtl directly represses TAp73 expression by forming a repressive 
complex with E2F1 at the TAp73 promoter. hSirtl activity is dependent on the intracellular 
redox state so that under conditions of low cellular NAD+ , hSirtl is inactivated, relieving 
TAp73 promoter inhibition.
1.4 E2Fl-dependent apoptosis is activated by genotoxic stress
1.4.1 E2F1 is activated by DNA damage
E2F1 was first implicated as a molecule activated by DNA damage when it was observed 
that cells treated with X rays or UVC irradiation upregulated E2F1 at the protein level in a 
manner analogous to that of p53. E2F1 is activated by the presence of DNA double strand breaks 
(DSBs), which causes its accumulation independent of de novo E2F1 RNA transcription 
(Blattner et al. 1999). It was observed that this increase in E2F1 protein levels is concomitant 
with an increase in DNA binding activity, which indicated an active role for E2F1 in the cellular 
response to DNA damage (Hofferer et al. 1999). Likewise, common chemotherapeutic agents 
that induce DNA double strand breaks (such as etoposide, cisplatin and doxorubicin) activate 
E2F1. Cells have a canonical signaling pathway that is activated by DSB accumulation. The 
DNA damage response pathway consists of detector kinases that identify DNA lesions and 
activate signal transducers and effectors, which mediate DNA repair, halt cell cycle progression 
and activate apoptosis. DNA damage is detected in cells by ataxia telangiectasia mutated (ATM) 
and the homologous ATMRad3-related (ATR) signaling kinases. While ATM primarily
recognizes DNA double strand breaks (such as those induced by ionizing radiation and 
topoisomerase inhibitors) and ATR primarily recognizes single strand breaks (such as those 
caused by ultraviolet (UV) radiation or stalled replication forks) there is extensive crosstalk 
between the single and double strand breaks arms of the DNA damage signaling cascades (Foray 
et al. 1997, Liu et al. 2000 and Guo et al. 2000). Once ATM/ATR are activated they 
phosphorylate p53 to induce cell cycle arrest and apoptosis as well as checkpoint kinases 
(CHK1/2) which inactivate cdc25 in order to halt S- phase progression (Banin et al. 1998, Roos 
and Kaina, 2006). It is now known that the observed DNA damage responsive increase in E2F1 
protein levels is because it is also targeted as part of the DNA damage signaling cascade. ATM 
phosphorylâtes E2F1 on serine-31 (Lin et al. 2001) while CHK2 phosphorylâtes E2F1 in its C- 
terminus on serine-364 (Stevens et al. 2003). These modifications are proposed to increase E2F1 
protein stability, therefore accounting for the transcription-independent upregulation of E2F1. 
E2F1 is also acetylated at lysines 117, 120 and 125 by p300/CREB-binding Protein-associated 
Factor (PCAF) which is thought to account for the observed increase in E2F1 DNA binding 
activity in response to DNA damage (Ianari et al. 2004). All of the DNA damage dependent post- 
translational modifications of E2F1 described have been shown to activate E2Fl’s apoptotic 
activity.
1.4.2 ATM phosphorylâtes serine 31
Phosphorylation of the N-terminus of E2F1 by ATM was the first identified DNA damage 
dependent post-translational modification of E2F1 (Lin et al. 2001). Many lines of evidence 
prompted the discovery that ATM directly phosphorylated E2F1 at serine 31. Firstly, it had been 
observed that E2F1 upregulation in response to DNA damage was reminiscent of p53 but
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independent of p53, a target of ATM phosphorylation during the DNA damage response. This 
prompted experiments demonstrating the requirement of ATM for E2F1 stabilization in response 
to DNA damage. The mapping of the residues S/Q or T/Q present at ATM/ATR phospho- 
acceptor sites (Kim et al. 1999; O’Neill et al. 2000) led to the identification of potential sites in 
E2F1. One site in particular, serine 31 seemed the most likely as the N-terminus of E2F1 had 
been previously demonstrated to be involved in regulating E2F1 degradation and thus could alter 
E2F1 stability (Marti et al. 1999) (Figure 1.5). Indeed a mutant of E2F1 that contained a serine 
31 to alanine mutation was unable to become stabilized in response to DNA damage, 
demonstrating for the first time a mechanism for DNA damage mediated upregulation of E2F1 
protein. It is now known that serine 31 phosphorylation of E2F1 stabilizes the protein by 
recruiting the phosphoserine binding protein 14-3-3t. 14-3-3x binds to E2F1 in a DNA damage 
dependent manner and inhibits E2F1 ubiquitination and degradation, thus increasing the stability 
of E2F1. 14-3-3x was shown to be required for the expression of E2F1 proapoptotic target genes 
such as TAp73 and caspases and depletion of either 14-3-3x or E2F1 inhibited apoptosis in 
response to DNA damage (Wang et al. 2004). More recent studies have implicated a role for 
serine-31 phosphorylated E2F1 in DNA repair. E2F1 accumulates at DNA damage foci and this 
accumulation was shown to be dependent on ATR kinase and serine 31 of E2F1 but not an intact 
DNA binding domain. As well, E2F1 depletion impairs the recruitment of nucleotide excision 
repair factors to sites of damage and reduces the efficiency of DNA repair (Guo et al. 2010).
1.4.3 PCAF acetylates lysines 117, 120, 125
Besides its DNA damage dependent phosphorylation, E2F1 is also acetylated in a DNA 
damage dependent manner (Pediconi et al. 2003). Acetylation of E2F1 was first described in a
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Figure 1.5. DNA damage dependent E2F1 post-translational modifications.
E2F1 is modified at the post-translational level in response to DNA damage. ATM phosphorylâtes 
E2F1 in its N-terminus on serine-31. CHK2 phosphorylâtes E2F1 in its C-terminus on serine-364. 
E2F1 is also acetylated at lysines 117, 120 and 125 near its DNA binding domain by p300/CREB- 
binding Protein-associated Factor (PCAF). These modifications are thought to increase E2F1 protein 
stability and DNA binding ability at proapoptotic promoters such as TAp73 and APAF-1.
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non-DNA damage dependent paradigm (Martinez-Balbas et al. 2000). It was identified that 
p300/CBP and the p300/CBP associated factor PCAF acetylated E2F1 in vitro and PCAF/E2F1 
complexes were isolated in asynchronously growing cells. Deletion analysis of E2F1 revealed 
that E2F1 is acetylated between residues 89-287, the region of E2F1 that contains the DNA 
binding domain. Mutational analysis of clusters of lysine residues between amino acids 89 and 
287 identified lysines 117, 120 and 125 (N-terminally adjacent to the DNA binding domain) as 
the residues acetylated by PCAF (Martinez-Balbas et al. 2000) (Figure 1.5). However, the 
requirement for acetylation of each of the three individual lysine residues in isolation has never 
been studied and so it is convention to assume all three sites are acetylated by PCAF, but this has 
never been shown directly. The acetylation of E2F1 increases its DNA binding ability and 
transactivation potential of a promoter bearing E2F-response elements (Martinez-Balbas et al. 
2000). PCAF dependent acetylation of E2F1 also increases its protein stability but the 
mechanism of this increased stability is unknown, apart from its dependence on the activity of 
the histone acetyltransferase domain of PCAF (Ianari et al. 2004). PCAF acetylation of E2F1 is 
further induced in response to DNA damage. The DNA damage dependent acetylation of E2F1 
occurs on the same residues as in asynchronously growing cells and experiments utilizing an 
E2F1 lysine 117, 120, 125 to arginine mutant that cannot be acetylated revealed that acetylated 
E2F1 contributes to activating E2F1 dependent apoptosis in response to DNA damage (Pediconi 
et al. 2003). Using acetylation-mimetic and mutant constructs of E2F1 that could not be 
phosphorylated at serine 31 or acetylated at lysine 117, 120 and 125 Pediconi et al. elegantly 
demonstrated the necessity of E2F1 DNA damage dependent post-translational modifications in 
recruiting E2F1 to the promoter of proapoptotic TAp73 and inhibiting recruitment to E2F1 cell 
cycle promoters, providing mechanistic insight into the regulation of E2F1 dependent apoptosis
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in response to DNA damage.
1.4.4 CHK2 phosphorylâtes serine 364
The DNA damage signaling kinase CHK2 also phosphorylâtes E2F1 (Stevens et al. 2003). 
A CHK2 consensus site was identified in the E2F1 C-terminus, just outside the marked box 
domain of E2F1. Experiments utilizing an E2F1 CHK2 consensus site mutant, E2F1-S364A, 
revealed that CHK2 phosphorylâtes E2F1 in vitro and in vivo at serine 364 (Stevens et al. 2003) 
(Figure 1.5). E2Fl-phospho-serine-364 can be endogenously detected in the nucleus of cells as 
little as two hours after treatment with the topoisomerase II inhibitor, etoposide. Like the other 
identified DNA damage dependent post-translational modifications described for E2F1, serine 
364 phosphorylation of E2F1 is important for E2F1-dependent apoptosis in a variety of cell lines 
and in response to DNA damage, independent of p53 status (Stevens et al. 2003). Experiments 
measuring the half life of wildtype E2F1 or a serine 364 to alanine mutant of E2F1 revealed that 
CHK2 phosphorylation increases E2F1 protein stability (Stevens et al. 2003). CHK2 
phosphorylation of E2F1 may increase its protein stability by inhibiting the addition of a methyl 
group at lysine 185 by the methylase Set9. Lysine-185 méthylation promotes the ubiquitylation 
and degradation of E2F1 (Kontaki and Talianidis, 2010), so 364-phosphorylation of E2F1 could 
exist to prevent E2F1 molecules being marked for degradation in response to DNA damage. 
Interestingly, it appears that serine 364 phosphorylation of E2F1 is important for its function as a 
transcription factor, as E2F1-S364A had a defect in its ability to activate transcription of even 
cell cycle targets (Stevens et al. 2003). In comparison to the other DNA damage dependent post- 
translational modifications of E2F1, little is known about the specific activity of serine-364 
phosphorylation by CHK2.
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1.5 An extra layer of complexity regulating pRB and E2F1 interactions
1.5.1 The identification o f an E2F1-specific binding cleft in the retinoblastoma protein
The identification of an E2F1 “specific” binding cleft in pRB highlights the complexity of 
pRB regulation of E2F1 activity among other E2Fs (Dick and Dyson 2003). The canonical way 
that pRB interacts with E2Fs is through a binding cleft in its “pocket domain” which consists of 
two cyclin folds and the pRB C-terminus (Figure 1.1) (Lee et al. 1998). However, in 2003 a 
study was published that described a second interaction domain in pRB that could bind only 
E2F1. This binding cleft was termed the E2F1 “specific site” and is located in the extreme C- 
terminus of pRB (residues 792-928). The pRB specific site binds the E2F1 marked box domain, 
unlike the pRB-E2Fl interaction mediated through the pocket domain and the E2F1 
transactivation domain. By this convention, E2F1-4 binding to pRB in the pocket domain is 
referred to as the “general” interaction or binding in the “general site” and E2F1 binding to pRB 
in the C-terminal binding cleft is referred to as the “specific” interaction. pRB/E2Fl complexes 
mediated through the general site have been demonstrated as necessary for cell cycle control, 
whereas pRB/E2F 1 complexes mediated through the specific site seem to be dispensable for cell 
cycle control, potentially because pRB/E2Fl specific complexes have a low affinity for binding 
to E2F response elements on the DNA. Instead, pRB binding to E2F1 in the specific 
conformation seems to regulate E2F1 induced apoptosis (Dick and Dyson 2003). This suggests 
an intricate level of regulation whereby different structural contacts between pRB and E2F1 
allows pRB to selectively regulate E2F1 dependent cell cycle progression or apoptosis.
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1.5.2 E2F1 has the unique ability to bind to hyperphosphorylatedpRB
While the accepted model of pRB regulation is that hypophosphorylated pRB is active and 
binds E2Fs and hyperphosphorylation of pRB renders it inactive and deficient for E2F binding, 
studies have identified the existence of pRB/E2Fl complexes in scenarios that would be 
expected to contain hyperphosphorylated pRB. For instance, a ChIP analysis identified 
pRB/E2Fl complexes at E2F target promoters in cells that were in S phase, a phase of the cell 
cycle where pRB should be hyperphosphorylated due to high CDK activity (Wells et al. 2003). It 
has been determined that in fact pRB can bind to E2F1 when it is hyperphosphorylated, a unique 
interaction among E2Fs that is dependent on the E2F1 specific binding cleft on pRB (Cecchini 
and Dick, 2011). The ability of E2F1 to bind to hyperphosphorylated pRB was mapped to a 
valine residue in E2Fl’s marked box domain that is not conserved among other E2Fs. In 
experiments done that exchanged regions of the E2F1 and E2F3 marked box domain it was 
observed that the presence of valine 276 (analogous to proline 329 in E2F3) was sufficient to 
confer binding ability of E2F3 to hyperphosphorylated pRB. Accordingly, mutation of E2F1 
valine 276 to proline (as is present in E2F3) diminished E2Fl’s capacity to interact with 
hyperphosphorylated pRB (Cecchini and Dick, 2011). While ppRB/E2Fl complexes have been 
identified and their biochemistry described, the function of these complexes has yet to be 
elucidated.
1.6 pRB is modified by DNA damage responsive signaling
1.6.1 pRB is modified at the post-translational level in response to DNA double strand
breaks
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Like E2F1, pRB is also modified at the post-translational level in response to DNA 
damage. pRB is acetylated on its C-terminus at lysines 873 and 874 by p300 (Chan et al. 2001 
and Markham et al. 2006) and phosphorylated at serine 612 by CHK2 (Inoue et al. 2007). 
Interestingly, both of these DNA damage responsive post-translational modifications of pRB 
regulate its ability to bind to E2F1. In experiments that utilized acetylation-mimetic or mutant 
constructs of pRB that contained lysine 873/874 to arginine substitutions it was suggested that 
acetylation of pRB decreased E2F1 binding in the C-terminal E2F1 specific site. This effect was 
unique to E2F1 as other pRB C-terminal binding partners such as MDM2 experienced no 
binding defects (Markham et al. 2006). In contrast, serine 612 phosphorylation of pRB is thought 
to increase pRB binding to E2F1, among other E2Fs. Subsequent work found that serine 612 
phosphorylation of pRB increases the formation of repressive pRB/E2Fl complexes and 
promotes the anti-apoptotic activity of pRB (Inoue et al. 2007). Therefore, the DNA damage 
responsive acetylation and phosphorylation of pRB seem to act in opposing ways and work that 
investigates the activity of both of these modifications in unison has yet to be published.
Most recently it was discovered that pRB is also methylated in response to DNA damage. 
pRB is methylated at lysines 810 and 873 by the Set7/9 methyltransferase, and at lysine 860 by 
the SMYD2 methyltransferase (Munro et al. 2010, Saddic et al. 2010, Carr et al. 2011). While 
relatively little is known about the function of methylated pRB during the DNA damage 
response, it was shown that lysine methylation has a role in inhibiting CDK-dependent 
phosphorylation of pRB and recruiting the heterochromatic protein HP1 to repressive pRB 
complexes on chromatin (Carr et al. 2011 and Munro et al. 2010). Likewise, a pRB mutant 
proposed to be defective for methylation by Set7/9 (pRB-810R) was defective for enrichment at 
E2F1 target genes (both cell cycle and apoptotic) compared to wildtype pRB in asynchronously
growing cells (Carr et al. 2011). Interestingly, a pRB-873A mutant was also shown to be 
defective for transcriptional repression of E2F1 target genes (Munro et al. 2001). The fact that it 
has been proposed that Set7/9 methylates both lysines 810 and 873 and p300 acetylates both 
lysines 873 and 874 clouds the interpretation of functional assays utilizing pRB-810 or 873/874 
substitution mutants. Coupled with the fact that the studies describing these sites do not take into 
account the presence of the other sites of post-translational modification, there exists a large 
disconnect in the interpretation of the functional role of DNA damage dependent pRB post- 
translational modifications.
1.6.2 Regulation o f pRB and E2F1 interactions in response to DNA damage
While data exists to explain the relationship between E2F1 and p53 in apoptosis, little 
congruous data exists to explain the role of pRB and E2F1 interactions during this process. The 
first studies of pRB’s regulation of E2F1 during apoptosis showed that loss of pRB sensitizes 
cells to DNA damage, as re-expression of pRB in Rb-null cell lines provides protection from 
DNA damage induced apoptosis (Almasan et al. 1995 and Knudsen et al. 2000) 
and siRNA mediated knockdown of Rb in human cancer cells sensitizes them to DNA damage 
induced apoptosis (Sun et al. 2010). Likewise, the expression of viral oncoproteins (such as 
El A) that inhibit pRB/E2F binding increase apoptosis via induction of TAp73 and Noxa, known 
E2F1 target genes (Flinterman et al. 2005). As the current dogma predicts, pRB seems to inhibit 
E2F1 dependent apoptosis, however, a recent study suggests a novel pro-apoptotic role for pRB 
(Ianari et al. 2009). This work demonstrated the presence of pRB at transcriptionally active pro- 
apoptotic promoters in response to DNA damage and that pRB expression is necessary for a 
maximal apoptotic response in vivo and in a variety of cell lines. There are other studies that also
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implicate pRB as having proapoptotic activity; ectopic expression of pRB that cannot be 
inactivated by cyclin/CDK complexes induces cell death (Knudsen et al. 1999), as well, re­
expression of pRB in RB deficient prostate cancer cells sensitizes them to gamma irradiation 
(Bowen et al. 2002). A caveat to interpreting the results from studies that utilize re-expression or 
siRNA mediated knockdown of pRB, however, is that pRB inhibits the Gl/S phase transition of 
the cell cycle. Therefore, apoptotic effects seen in these systems that are interpreted as a 
consequence of proapoptotic pRB signaling may simply be secondary effects due to altered cell 
proliferation when pRB is re-introduced or lost. These confounding reports, which consist mostly 
of studies of ectopically expressed proteins, leave the question of the contribution of the pRB- 
E2F1 interaction to apoptotic induction open to further investigation as a clear understanding or 
mechanism is currently lacking.
Previous work in our lab examined the relative contribution of phosphorylated serine 31, 
364 or acetylated lysines 117, 120 and 125 to E2Fl’s ability to bind to its most prevalent 
inhibitor, pRB, a yet unappreciated interaction involved in E2Fl’s regulation of the DNA 
damage response and apoptosis. Our lab discovered that DNA damage induced modifications of 
E2F1 affect its ability to form a complex with pRB, resulting in a pool of E2F1 “free” of pRB 
binding in response to DNA double-strand breaks. In order to determine the relative contribution 
of each post-translational modification of E2F1 to apoptotic induction our lab transduced cells 
with E2F1 cDNAs deficient for each modification site and assayed their ability to bind to pRB. It 
was discovered that in response to DNA damage, cells that had been transduced with wildtype 
E2F1 had a decreased ability to form complexes with pRB when compared to cells that had been 
transduced with E2F1-TM (unable to be phosphorylated or acetylated at DNA damage 
responsive sites). The ability of E2F1-S364 to be phosphorylated seemed to have no effect on
pRB binding. This work led to the hypothesis that DNA damage responsive post-translational 
modifications on E2F1 (S31 phosphorylation and lysines 117, 120 and 125 acetylation) 
“released” E2F1 from pRB binding to generate a molecular pool of “free” proapoptotic E2F1 in 
cells that had incurred DNA damage (Figure 1.6). This work, done previously in our lab, has 
uncovered some important details in regards to the ability of E2F1 to bind to pRB following 
DNA damage, however the experiments were done using exogenously expressed E2F1 and 
therefore provided a useful working model of E2F1 and pRB binding dynamics but do not 
directly address what is happening in vivo in response to DNA damage. While these experiments 
and the relevant literature provide compelling data that E2F1 post-translational modifications 
activate apoptosis following DNA damage and affect pRB binding ability, these studies all 
utilized transfection based experiments. What is missing from the study of E2F1 and pRB 
binding in response to DNA damage are experiments that directly investigate endogenous 
cellular interactions.
1.7 Hypothesis and Thesis Objectives
In light of contradictory reports in the primary literature, a clear mechanism to explain the 
contribution of post-translational modifications in regulating endogenous E2Fl-pRB interactions 
following DNA damage and their effect on apoptosis has yet to be elucidated. In order to begin 
to provide answers to this fundamental question I first focused my study on E2F1 DNA damage- 
dependent post-translational modifications. I hypothesize that DNA damage induced post- 
translational modification of E2F1 generates distinctly modified molecular pools of E2F1 which 
participate in pRB complexes that have discrete functionality. To investigate the contribution of 
endogenous pRB and E2F1 proteins to DNA damage induced apoptosis I aimed to investigate
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the regulation of endogenous pRB/E2Fl complex formation following DNA damage and 
investigate apoptotic induction mediated by E2F1 post-translational modifications following 
DNA damage.
In chapter 3.1-3.3,1 investigate endogenous pRB/E2Fl complex formation in response to 
DNA damage and determine that DNA double strand breaks increase pRB-E2Fl binding. In 
chapter 3.4,1 characterize the post-translational modifications present on E2F1 in complex with 
pRB and discover that CHK2 phosphorylated E2F1 is found exclusively bound to pRB following 
DNA damage. In chapter 3.5 and 3.6,1 characterize the post-translational modifications present 
on pRB and E2F1 in complex following DNA damage. Specifically, I isolate two distinct 
pRB/E2Fl complexes that can be differentiated based on their post-translational modifications. I 
determine that CHK2 phosphorylated E2F1 forms a unique complex with hyperphosphorylated 
pRB that excludes other post-translational modifications and that acetylated E2F1 and pRB 
comprise the second pRB/E2Fl complex that includes primarily hypophosphorylated pRB. In 
chapters 3.8-3.10 I investigate the functional role of E2F1 post-translational modifications in 
response to DNA damage. I utilize a genetic system of reconstitution of E2F1 substitution 
mutants deficient for the ability to be phosphorylated or acetylated in response to DNA damage 
in immortalized E2fl-/- cells. I demonstrate that the functional role of all E2F1 post-translational 
modifications is to activate TAp73 gene expression and induce apoptosis in response to DNA 
damage and that each modification has an additive effect. A recent study suggested a novel pro- 
apoptotic, transcriptionally active role for hyperphosphorylated pRB in response to DNA damage 
(Ianari et al. 2009). In chapters 3.4 and 3.6 I demonstrate that CHK2 phosphorylated E2F1 forms 
a unique complex with hyperphosphorylated pRB and in chapters 3.9 and 3.10 I demonstrate that 
the role of serine 364 phosphorylation of E2F1 is to activate TAp73 expression and induce
32
apoptosis in response to DNA damage. Taken together, these results provide a mechanism for the 
novel discovery of ppRB’s proapoptotic activity, whereby it forms a transcriptionally active 
proapoptotic complex with CHK2-phosphorylated E2F1 in response to DNA damage.
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Figure 1.6. Initial working model of the role of E2F1 post-translational modifications in 
regulating pRB/E2Fl complex formation in response to DNA damage.
DNA damage induced modifications of E2F1 affect its ability to form a complex with pRB, resulting in 
a pool of E2F1 “free” of pRB binding in response to DNA double-strand breaks (top left panel). This 
effect is lost in a mutant of E2F1 that cannot be modified following DNA damage (bottom left panel). 
DNA damage results in two populations of E2F1 that can be fractionated based on their post- 
translational modifications and ability to bind to pRB. The E2F1 populations have distinct functionality 
in that “free” E2F1 functions in apoptosis and DNA repair and pRB-bound E2F1 regulates the cell 
cycle (right panel).
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CHAPTER 2: MATERIALS AND METHODS
obtained from Jiang Zhou (University of Rochester). CMV-HA-E2F1 and CMV-HA-DP1 have 
been described previously (Dick FA. 2003). pBABE-puro was obtained from R. Hurford. 
pB ABE-HA-E2F1 was constructed by cloning the blunted HINDIII-Notl fragment containing 
HA-E2F1 (from CMV-HA-E2F1) into the blunted EcoRI site of the pBABE polylinker, 
constructed by Fred Dick. pBABE-HA-E2Fl-KR was constructed by cloning the blunted 
Hindlll-Notl fragment containing HA-E2F1 (from CMV-HA-E2F1-KR) into the blunted EcoRI 
site of the pBABE polylinker, obtained from Alberto Gulino. pBABE-HA-E2Fl-DM was 
constructed by cloning the blunted Hindlll-Notl fragment containing HA-E2F1 (from CMV-HA- 
E2F1-DM) into the blunted EcoRI site of the pBABE polylinker, constructed by Fred Dick. 
pBABE-HA-E2Fl-S364A was constructed by cloning the blunted Hindlll-Notl fragment 
containing HA-E2F1 (from CMV-HA-E2F1-S364A) into the blunted EcoRI site of the pBABE 
polylinker, constructed by Fred Dick. pBABE-HA-E2Fl-TM was constructed by cloning the 
blunted Hindlll-Notl fragment containing HA-E2F1 (from CMV-HA-E2F1-TM) into the blunted 
EcoRI site of the pBABE polylinker, constructed by Oliva Palander. pBABE expression 
plasmids were used for infection along with the pMOV-y plasmid encoding Gag, Pol and Env 
genes. pBABE-E2Fl-TM, -DM and S364A mutants were used for retroviral infection of murine 
E2fl-/- 3T3 and studied during functional assays. pBABE-puro-E2Fl-TM contains an E2F1 
cDNA with a serine 31 to alanine, lysines 117, 120 and 125 to arginine mutations and a serine 
364 to alanine mutation. pBABE-puro-E2Fl-DM contains human E2F1 cDNA with a serine 31 
to alanine and lysines 117, 120 and 125 to arginine mutation. pBABE-puro-E2Fl-S364A 
contains human E2F1 cDNA with a serine 364 to alanine mutation.
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2.3 Antibody Epitope Mapping Using SPOT Peptide Arrays
An array of 159 15-mer E2F1 peptides each with a one amino acid overlap were 
synthesized (Li, S. UWO) with full coverage of the N-terminus (amino acids 1-90) and C- 
terminus (amino-acids 341-437) of human E2F1. Peptides were synthesized as spots onto a 
nitrocellulose membrane and dried (full procedure described in Reineke and Sabat, 2008), see 
table 2.2 for peptide identities. Determination of E2F1 antibody epitopes (KH20 monoclonal and 
C20 rabbit polyclonal, Santa Cruz) began by first rehydrating the dried nitrocellulose peptide 
SPOT membrane. The membrane was incubated in ethanol for 1 minute, distilled water was 
added to 50% and incubated for 15 minutes. The membrane was then washed in 100% distilled 
water 3 times for 15 minutes each followed by 3 washes in Tris buffered saline-0.1% Tween20 
(TBST-20mM Tris pH 7.5, 150mM NaCl, 0.1% Tween20) for 10 minutes each. The membrane 
was then blocked for 3 hour at room temperature by incubation in 5% nonfat milk-TBST. The 
membrane was then washed 3 times for 10 minutes each in TBST and incubated with primary 
E2F1 antibody (KH20 or C20) at a concentration of 0.2pg/mL diluted in 5% nonfat milk-TBST. 
The membrane was then blocked for 3 hour at room temperature by incubation in 5% nonfat 
milk-TBST. The membrane was then washed 3 times for 10 minutes each in TBST and 
incubated with peroxidase-labeled secondary antibody (anti-mouse and anti-rabbit for KH20 and 
C20, respectively) at a concentration of lpg/mL for 1 hour at room temperature. The membrane 
was then washed 3 times for 10 minutes each in TBST and developed using chemiluminescence 
detection solution (0.1M Tris pH 8.5, 390pM coumaric acid, 2.46mM luminol, 0.02% H2O2) and 
a 5 second exposure to Amersham hyperfilm (GE Healthcare).
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Table 2.2 Description of Peptides in SPOT Peptide Array
Peptide # N-Terminal peptide 
sequence
Peptide # C-Terminal peptide 
sequence
1 malagapaggpsapa 77 slttdpsqsllsleq
2 alagapaggpsapal 78 lttdpsqsllsleqe
3 lagapaggpsapale 79 ttdpsqsllsleqep
4 agapaggpsapalea 80 tdpsqsllsleqepl
5 gapaggpsapaleal 81 dpsqsllsleqepll
6 apaggpsapaleall 82 psqsllsleqeplls
7 paggpsapaleallg 83 sqsllsleqepllsr
8 aggpsapaleallga 84 qsllsleqepllsrm
9 ggpsapaleallgag 85 sllsleqepllsrmg
10 gpsapaleallgaga 86 llsleqepllsrmgs
11 psapaleallgagal 87 lsleqepllsrmgsl
12 sapaleallgagalr 88 sleqepllsrmgslr
13 apaleallgagalrl 89 leqepllsrmgslra
14 paleallgagalrll 90 eqepllsrmgslrap
15 aleallgagalrlld 91 qepllsrmgslrapv
16 leallgagalrllds 92 epllsrmgslrapvd
17 eallgagalrlldss 93 pllsrmgslrapvde
18 allgagalrlldssq 94 llsrmgslrapvded
19 llgagalrlldssqi 95 lsrmgslrapvdedr
20 lgagalrlldssqiv 96 srmgslrapvdedrl
21 gagalrlldssqivi 97 rmgslrapvdedrls
22 agalrlldssqivii 98 mgslrapvdedrlsp
23 galrlldssqiviis 99 gslrapvdedrlspl
24 alrlldssqiviisa 100 slrapvdedrlsplv
25 lrlldssqiviisaa 101 lrapvdedrlsplva
26 rlldssqiviisaaq 102 rapvdedrlsplvaa
27 lldssqiviisaaqd 103 apvdedrlsplvaad
28 ldssqiviisaaqda 104 pvdedrlsplvaads
29 dssqiviisaaqdas 104 vdedrlsplvaadsl
30 ssqiviisaaqdasa 105 dedrlsplvaadsll
31 sqiviisaaqdasap 106 edrlsplvaadslle
32 qiviisaaqdasapp 107 drlsplvaadslleh
33 iviisaaqdasappa 108 rlsplvaadsllehv
34 viisaaqdasappap 109 lsplvaadsllehvr
35 iisaaqdasappapt 110 splvaadsllehvre
36 isaaqdasappaptg 111 plvaadsllehvred
37 saaqdasappaptgp 112 lvaadsllehvredf
38 aaqdasappaptgpa 113 vaadsllehvredfs
39 aqdasappaptgpaa 114 aadsllehvredfsg
40 qdasappaptgpaap 115 adsllehvredfsgl
41 dasappaptgpaapa 116 dsllehvredfsgll
42 asappaptgpaapaa 117 sllehvredfsgllp
43 sappaptgpaapaag 118 llehvredfsgllpe
44 appaptgpaapaagp 119 lehvredfsgllpee
45 ppaptgpaapaagps 120 ehvredfsgllpeef
46 paptgpaapaagpsd 121 hvredfsgllpeefi
47 aptgpaapaagpsdp 122 vredfsgllpeefis
48 ptgpaapaagpsdpd 123 redfsgllpeefisl
49 tgpaapaagpsdpdl 124 edfsgllpeefisls
50 gpaapaagpsdpdll 125 dfsgllpeefislsp
51 paapaagpsdpdlll 126 fsgllpeefislspp
52 aapaagpsdpdlllf 127 sgllpeefislspph
53 apaagpsdpdlllfa 128 gllpeefislspphe
54 paagpsdpdlllfat 129 llpeefislspphea
55 aagpsdpdlllfatp 130 lpeefislsppheal
56 agpsdpdlllfatpq 131 peefislsppheald
57 gpsdpdlllfatpqa 132 eefislspphealdy
58 psdpdlllfatpqap 133 efislspphealdyh
59 sdpdlllfatpqapr 134 fislspphealdyhf
60 dpdlllfatpqaprp 135 islspphealdyhfg
61 pdlllfatpqaprpt 136 slspphealdyhfgl
62 dlllfatpqaprptp 137 lspphealdyhfgle
63 lllfatpqaprptps 138 spphealdyhfglee
64 llfatpqaprptpsa 139 pphealdyhfgleeg
65 lfatpqaprptpsap 140 phealdyhfgleege
66 fatpqaprptpsapr 141 healdyhfgleegeg
67 atpqaprptpsaprp 142 ealdyhfgleegegi
68 tpqaprptpsaprpa 143 aldyhfgleegegir
69 pqaprptpsaprpal 144 ldyhfgleegegird
70 qaprptpsaprpalg 145 dyhfgleegegirdl
71 aprptpsaprpalgr 146 yhfgleegegirdlf
72 prptpsaprpalgrp 147 hfgleegegirdlfd
73 rptpsaprpalgrpp 148 fgleegegirdlfds
74 ptpsaprpalgrppv 149 gleegegirdlfdsd
75 tpsaprpalgrppvk 150 leegegirdlfdsdf









2.4 Production and Purification of a Phospho-serine-31-E2Fl Specific Polyclonal Antibody
Covance Research Products Inc. was hired to produce the phospho-serine-31-E2Fl 
Specific Polyclonal Antibody. Two rabbits were immunized with a soluble KLH-conjugated 11 
amino acid phospho-peptide surrounding the human E2F1 serine 31 sequence ( [H]-CKKKLDS- 
pS-QIV-[NH2]) using a standard 118 day protocol. Animals followed a 3 week cycle of antigen 
boosts and test bleeds were taken 10 days following the boosts. Serum from test bleeds was used 
for initial ELISA screening to determine the effect of the antigen on the animal. Approximately 
115mL of serum was obtained in total and purified in 5mL batches. Purification of phospho- 
serine-31-E2Fl specific polyclonal IgGs resulted from a 2 step immunoaffinity column 
chromatography procedure. Phospho-serine-31-E2Fl and non-phospho-serine-31-E2Fl 
immunoaffinity columns were prepared using the phospho [H]-CKKKLDS-pS-QIV-[NH2] 
peptide sequence rabbits were immunized with and also a non-phospho peptide sequence [H]- 
CKKKLDS-S-QIV-[NH2], respectively. Peptides were first reduced by incubation with 
immobilized TCEP reducing gel (2mL gel per mg of peptide, Pierce) for 15 minutes at room 
temperature in a gravity flow column. Reduced peptides were eluted in 0.5mL fractions and the 
fractions containing the highest peptide concentrations (determined by BCA protein assay, 
Pierce) were pooled and coupled to 4mL each of Sulfolink Coupling gel (Pierce). Non-specific 
binding sites on the gel were blocked with 50mL L-cysteine HCL and washed with 1M NaCl. 
Antibody purification proceeded by first clearing the serum of debris by centrifugation at 4°C at 
2800 rpm for 10 minutes. The cleared serum was then incubated with the phospho-serine-31- 
E2F1 peptide coupled column rocking at 4°C for 2 hours. The unbound supernatant was 
discarded and bound IgG was eluted in lmL fractions with 0.2M glycine pH 2.5 and 
immediately neutralized with 95 pL of 1.5M Tris pH 8.5. Non-phospho and pan-specific E2F1
antibodies were removed from the eluate by incubation with the non-phospho-E2Fl -peptide 
bound column (as described above) and collecting the unbound flow through. Post-purification 
both columns were regenerated by washing with lOmL of 0.2M glycine pH 1.9 followed by 
30mL of lxPBS with 0.02% NaN3 and stored for future use at 4°C. The purified phospho-serine- 
31-E2F1 specific polyclonal antibody was dialyzed against lL/mL of lxPBS overnight and 
diluted in storage buffer (lxPBS, 20% glycerol, 0.01% NaNs), made into lOOpL aliquots and 
stored at -20°C.
2.5 Recombinant Protein Purification
GST-RBLP (large pocket domain of pRB-cDNA cloned into pScodon, Delphi Genetics ) 
and GST-E2F1 or GST-E2F1-S31A (cDNA cloned into pGEX 4T-2) GST fusion proteins were 
expressed in BL21-DE3-Gold E.coli. Transformed E.coli were streaked onto LB-amp plates and 
incubated overnight at 37°C. Single colonies were picked the next day and inoculated in 25mL 
cultures of LB-amp and grown overnight in lOOmL flasks at room temperature. The following 
day the 25mL culture was used to inoculate 500mL of LB-amp in a 2L flask and grown until an 
O.D of 0.4 after which 100pM Isopropyl P-D-l-thiogalactopyranoside (IPTG) was added to 
induce protein expression. Induced cultures were incubated overnight at 16°C and bacterial 
pellets were collected the next morning by centrifugation at 2800rpm for 20 minutes. Pellets 
were washed with 25mL of ice cold water and re-pelleted as before. Pellets were lysed in lOmL 
of lysis buffer (20mM Tris pH 7.5, 0.5M NaCl, 0.5mM EDTA, 10% glycerol, 0.5% NP40, ImM 
DTT, 0.25mM PMSF) and sonicated on ice with 3x20s pulses. Cell debris was pelleted at 
2800rpm for 30 minutes and cleared supernatants were added to 600pL of 50% glutathione 
sepharose slurry (GE healthcare) and incubated rotating at 4°C for 1 hour. Beads were then
45
washed with lOmL of high salt lysis buffer (20mM Tris pH 7.5, 1M NaCl, 0.5mM EDTA, 10% 
glycerol, 0.5% NP40, ImM DTT, 0.25mM PMSF ) 3 times, followed by 5 washes in lOmL of 
lysis buffer and 1 wash in lOmL of KCL buffer (20mM Tris pH 7.5, 0.1M KC1, 10% glycerol, 
ImM DTT, 0.25mM PMSF). GST-proteins were eluted by incubation in 500pL elution buffer 
(50mM Tris pH 8, 0.1M KC1, 10% glycerol, ImM DTT, 0.25mM PMSF, 200mM glutathione) 
for 30 minutes on ice. Eluted proteins were dialyzed overnight against 1000X excess of KC1 
buffer at 4°C.
2.6 Enzyme Linked Immunosorbent Assay
ELISA screening was performed to test binding specificity of the phospho-serine-31-E2Fl 
specific polyclonal IgG. Phospho-serine-31-E2Fl and non-phospho-serine-31-E2Fl peptides 
along with a pRB C l5 peptide (positive control) and no peptide (negative control) were assayed. 
0.3 jig of peptides (or TBS in the case of the no peptide negative control) were added in triplicate 
to the wells of a flat bottom 96 well dish (Falcon). The plate was incubated for 5 hours at room 
temperature to adsorb the peptides to the bottom of the wells after which the supernatant was 
removed and 50pL of blocking buffer (1XPBS, 3%BSA) was added for 2 hours at room 
temperature. Wells were washed 3 times in TBST (20mM Tris pH 7.5, 150mM NaCl, 0.1% 
Tween20) after which 30pL of a titration (1/10, 1/100, 1/1000, 1/10000, 1/100000, 1/1000000, 
1/100000000 in blocking buffer) of purified phospho-serine-31-E2Fl specific polyclonal IgG or 
anti-pRB C l5 primary antibody (positive control) was added and incubated for 1 hour at room 
temperature. Wells were washed 5 times in TBST after which 30pL of 1 pg/mL goat-anti rabbit 
secondary antibody conjugated to alkaline phosphatase (Sigma) dissolved in blocking buffer was 
incubated with each well for one hour at room temperature. Wells were washed 3 times in TBST
after which 50pL of Alkaline Phosphatase Yellow (pNPP) Liquid Substrate System for ELISA 
(Sigma) was added to develop the yellow signal for colourimetric analysis by reading absorbance 
at 405nm on a Wallac-Victor plate reader.
2.7 In Vitro Kinase Assays
In vitro kinase assays tested the ability of ATM or CDK2 to phosphorylate GST-E2F1 or 
GST-E2F1-S31A recombinant protein. U20S were plated at a density of lxlO6 cells per 10cm 
tissue culture dish (Coming) and transfected the following day with either 15pg of CMV-Flag- 
ATM or 7.5pg each of CMV-HA-CDK2 and CMV-HA-cyclin E using a standard calcium/HBS 
protocol. Briefly, plasmid DNA was added to 500pL of 2X HBS pH 7.0 (280mM NaCl, 1.5mM 
Na2HP0 4 *7 H2 0 , 50mM HEPES) and the total volume was made up to 950pL with sterile water. 
One sample at a time, 50pL of 2.2M CaCh was added dropwise and the sample was vortexed 
immediately for 10 seconds. The transfection mixture was added dropwise to 10cm dishes of 
50% confluent U20S containing 8mL of culture media and allowed to precipitate overnight. The 
next morning the transfection mixture was removed, cells were washed in 1XPBS and re-fed 
with lOmL of media. Fourty-eight hours post-transfection cells were collected, washed 2 times in 
1XPBS and cell pellets were flash frozen in a dry ice/ethanol bath and stored at -80°C until lysis. 
The day the kinase assay was performed ,cells were lysed for 20 minutes on ice in 500pL of 
TGN lysis buffer containing protease and phosphatase inhibitors (50mM Tris pH 7.5, 150mM 
NaCl, 0.3% NP40, 1% Tween-20, 5mM NaF, ImM Na3V04, ImM PMSF, 2pg/mL pepstatin A, 
5pg/mL leupeptin, 10(ig/mL apoprotinin, ImM DTT). Extracts were cleared by centrifugation at 
lOOOOrpm for 10 minutes and added to 50pL of protein G dynabeads (Invitrogen) pre-bound to 
4pg of non-specific rabbit or mouse IgG (depending on the primary antibody species used to
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immunoprecipitate the kinase) and rotated at 4°C for 45 minutes. Cleared supernatants were 
transferred to 50pL of protein G dynabeads pre-bound to 4pg of mouse anti-flag (M2 Sigma) to 
immunoprecipitate flag-ATM or rabbit anti-CDK2 (H-298 Santa Cruz) to immunoprecipitate 
CDK2/cyclinE and rotated at 4°C for 1.5 hours. The anti-flag antibody-bead complexes were 
washed 1 time in TGN buffer, 1 time in TGN buffer with 0.5M LiCl and 2 times in kinase buffer 
(20mM HEPES pH7.5, 50mM NaCl, lOmM MgCb, lOmM MnCb, ImM DTT). The anti-CDK2 
antibody-bead complexes were washed 2 times in TGN buffer and 2 times in CDK2 kinase 
buffer (20mM Tris pH 7.5, 50mM NaCl, lOmM MgCl2, ImM DTT). Washed antibody-bead 
complexes were resuspended in their respective kinase buffers to which lOpCi [y P]ATP and 
1 pg of GST-E2F1 or GST-E2F1-S31A was added in a total reaction volume of 50pL. In vitro 
phosphorylation was allowed to proceed for 20 minutes at 30°C after which lOpL of ATM or 
CDK2 phosphorylated GST-E2F1 or GST-E2F1-S31A was added to protein G dynabeads pre­
bound to 4pg of phospho-serine-31-E2Fl specific polyclonal IgG or rabbit IgG as a negative 
control and rotated at 4°C for 1.5 hours. Antibody-bead complexes were washed 3 times in TGN 
buffer and complexes were eluted in 50pL of Laemmli sample buffer (0.25M Tris pH 6.8, 10% 
glycerol, 5% sodium dodecyl sulfate, 0.05% bromophenol blue, 5% beta-mercaptoethanol) at 
95°C and analyzed by SDS-PAGE followed by autoradiography.
2.8 Immunoprécipitation and Western Blot Analysis
Quantitative immunoprécipitations were performed on 5mg of endogenous U20S nuclear 
extract. U20S were cultured in 15cm dishes to 80% confluency, treated with lOOpM etoposide 
(Sigma) for 8 hours after which cells were washed 2 times in 1XPBS, collected with a cell 
scraper and pelleted at 1600 rpm for 5 minutes at 4°C. Pellets were resuspended in 5mL of
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hypotonic lysis buffer (lOmM Tris pH7.5, lOmM KC1, 3mM MgCl2, ImM EDTA, ImM DTT, 
ImM PMSF, 5mM NaF, O.lmM Na3V0 4 , 5(ig/mL leupeptin, 5pg/mL aprotinin) for 5 minutes 
on ice, after which NP40 was added to 0.05% for 5 minutes to lyse the cytoplasmic 
compartment. Nuclei were pelleted at 4000rpm for 10 minutes at 4°C, the supernatant was 
removed and nuclei were lysed on ice for 25 minutes in GSE lysis buffer (20mM Tris pH7.5, 
420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 25mM DTT, 25% glycerol, ImM PMSF, 5mM 
NaF, O.lmM Na3VC>4, 5pg/mL leupeptin, 5|ig/mL aprotinin). Nuclear extracts were cleared by 
centrifugation at lOOOOrpm at 4°C for 10 minutes to pellet nuclear debris and the supernatant 
containing the soluble nuclear fraction was collected. NaCl concentration was corrected to 
150mM in nuclear extracts using NaCl-free low salt GSE buffer (20mM Tris pH 7.5, 1.5mM 
MgC12, 0.2mM EDTA, 25mM DTT and 0.1% NP- 40) and extracts were diluted to a 
concentration of 2mg/mL. Extracts were pre-cleared with 50pL of protein G dynabeads pre­
bound to 4pg of non-specific rabbit IgG and rotated at 4°C for 45 minutes. The cleared 
supernatant was removed and incubated with 200pL of protein G dynabeads pre-bound to 
lmg/mL of purified anti-pRB Cl 5 rabbit polyclonal antibody (Proteintech) and incubated 
overnight rotating at 4°C. The next morning, the supernatant was removed and re-incubated with 
80pL of new protein G dynabeads pre-bound to lmg/mL of purified anti-pRB Cl 5 rabbit 
polyclonal antibody for 2 hours rotating at 4°C and the 200pL of antibody-bead complexes were 
pooled and stored on ice. After the second depletion of pRB complexes the supernatant was 
removed and incubated with 200pL of protein G dynabeads pre-bound to lmg/mL of purified 
anti-E2Fl C20 rabbit polyclonal antibody (Santa Cruz) for 8 hours rotating at 4°C in a sequential 
immunoprécipitation reaction. Finally, all antibody-bead complexes were collected, washed 3 
times each in lmL of low salt GSE buffer and eluted in 200pL of IX Laemmli buffer at 95°C
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and analyzed by SDS-PAGE on an 8% gel. Proteins were transferred to a nitrocellulose 
membrane followed by western blot for E2F1 (KH20, Santa Cruz), pRB (BD Pharmingen), Ac- 
lys (Clone 4G12, Millipore) and phospho-serine-364-E2Fl (Rockland). All antibodies were used 
at a dilution of 1/1000 of the stock in blocking buffer (1% nonfat milk or 5% BSA in the case of 
anti-Aclys and anti-Phospho-serine-364-E2Fl ). A “pre” gel was run for each quantitative IP to 
demonstrate the complete depletion of pRB complexes and normalize for loading of E2F1 in the 
anti-C15 and anti-C20 immunoprécipitation samples.
Anti-Phospho-serine-364-E2Fl and anti-C20 non-quantitative immunoprécipitations were 
performed as above but with the following modifications: 2mg of nuclear extract was used, 2pg 
of anti-Phospho-serine-364-E2Fl or C20 was pre-bound to 50pL of protein G dynabeads, 
immunoprécipitations were performed overnight at 4°C and eluted in 50pL of sample buffer. A 
rabbit IgG immunoprécipitation in equal quantities was run in parallel as a negative control for 
all immunoprécipitation experiments. See Table 2.3 for a full description of antibodies used.
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Table 2.3 Description of Antibodies




E2F1, serine 31 
phosphorylated Rabbit
immunoprécipitation 




C20 E2F1 Rabbit immunoprécipitation, western blot Santa Cruz
KH20 E2F1 Mouse western blot Santa Cruz
M2 Flag-epitope Mouse immunoprécipitation Sigma
12CA5 HA-epitope Mouse immunoprécipitation hybridomasupernatant
G3-245 pRB Mouse western blot BD Pharmingen












Anti-CDK2 CDK2 Rabbit immunoprécipitation UpstateBiotechnology
Anti-Actin
A2066 actin Rabbit western blot Sigma
Anti-BrdU




p53, serine 15 
phosphorylated Rabbit western blot Cell Signaling
anti-lamin
A/C3211
lamin, A and C 




2.9 Retroviral Transduction and 3T3 Culture
E2fl-/- 3T3 were retrovirally transduced at passage 21 with the following vectors: pBABE- 
puro-E2Fl-WT, -TM, -DM and -S364A. pBABE-puro-E2Fl-WT contains wildtype human E2F1 
cDNA. pBABE-puro-E2Fl-TM contains a human E2F1 cDNA with a serine 31 to alanine, 
lysines 117, 120 and 125 to arginine mutations and a serine 364 to alanine mutation. pBABE- 
puro-E2Fl-DM contains human E2F1 cDNA with a serine 31 to alanine and lysines 117, 120 
and 125 to arginine mutation. pBABE-puro-E2Fl-S364A contains human E2F1 cDNA with a 
serine 364 to alanine mutation. pBABE-puro was used as an empty vector control. Briefly, 
Phoenix-Eco retroviral packaging cells were plated at a density of 11 million cells per 15cm dish 
in 20mL of complete media 1 day before transfection. 4 hours pre-transfection 20mL of fresh 
media was added. Phoenix-Eco were transfected with 45 pg of pBABE-puro or pBABE-puro 
containing a human E2F1 cDNA along with 30pg of pMOV-\|/. 12 hours post-transfection cells 
were re-fed with fresh media and viral supernatants were collected 48 hours post-transfection, re­
fed , and re-collected 72 hours post-transfection after which the Phoenix-Eco cells were disposed 
of in a biohazard material container. 15mL of media was collected from each transfected plate at 
each viral supernatant collection and passed through a 0.45pm filter. Polybrene (Sigma) was 
added to a concentration of 4pg/mL and the entire viral supernatant (15mL each time) was added 
to a 15cm dish of 60% confluent E2fl-/- 3T3s. Each infection was allowed to take place for 12 
hours. After two rounds of viral infection the viral supernatant was removed and 25mL of fresh 
media containing 4pg/mL puromycin was added for 4 days to select infected cells. Cells were 
then passaged once after which they were immediately plated and used for functional assays. 
Prolonged culture or freezing of E2F1 -reconstituted E2fl-/- 3T3s was not compatible with their 
use in functional assays as E2F1 post-translational modification dependent phenotypes were lost.
53
Cell cycle analysis was performed by measuring BrdU incorporation by flow cytometry for 
E2F1-reconstituted 3T3s. Cells were plated at a density of lxlO6 cells per 10cm dish 1 day prior 
to cell cycle analysis. The following day cells were pulse labeled for 1 hour with 40pL of BrdU 
(GE Healthcare), washed twice in lxPBS and collected by incubation in 1XPBS with 3mM 
EDTA. Cells were pelleted, resuspended in 100pL of 1XPBS and fixed by the dropwise addition 
of 90% ethanol slowly while vortexing. After 30 minutes of fixation, DNA was denatured and 
cells were permeabilized by the dropwise addition of lmL of 2N HC1 with 0.5% triton X. After 
30 minutes cells were neutralized by the addition of 0.1M NaB40 7  pH 8.5. After 30 minutes 
cells were pelleted and resuspended in 1/50 mouse anti-BrdU primary antibody (BD-Bioscience) 
resuspended in 500pL 1XPBS with 1% BSA and 0.2% Tween20 for 1 hour at room temperature. 
Cells were pelleted and resuspended in 250pL of secondary anti-mouse IgG conjugated to FITC 
diluted at 1/100 in 1XPBS with 1% BSA and 0.2% Tween20 protected from light for 30 minutes 
at room temperature. Cells were then pelleted and resuspended in 500pL of propidium iodide 
DNA stain (200pL of 50X PI, 250pL 40X RNase, 9.7mL of IX PBS with 1% BSA) and 
incubated protected from light overnight at 4°C. The following day cells were passed through a 
cell strainer (Becton Dickson) and analyzed by flow cytometry. Results are represented as the 
average of three independent experiments.
Cell proliferation of E2F1-reconstituted 3T3s was measured by performing a 6 day growth 
curve. Cells were plated in triplicate at a density of 5xl04 cells per well in a 6 well tissue culture 
dish. Beginning 24 hours post-plating, each well was trypsinized, resuspended in lmL of 1XPBS 
and cell number was determined using a hemocytometer.
2 . 1 0  G r o w t h  A n a l y s i s
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Real-time quantitative PCR was used to quantitate gene expression of the TAp73 and 
cyclinA2 loci in E2F1-reconstituted 3T3s in response to 6 hour treatment with lOOpM etoposide. 
RNA was extracted using 500pL of TRIzol reagent (Invitrogen) per 10cm dish of cells. The 
manufacturer’s recommended protocol was followed. Briefly, cells were washed 2 times in 
1XPBS after which TRIzol reagent was added for 5 minutes while rotating to lyse cells. 
Supernatants were collected and the aqueous phase containing RNA was extracted using lOOpL 
of chloroform and centrifuging at 13000rpm for 10 minutes. RNA was precipitated with 500pL 
of isopropanol and RNA pellets were washed with 75% ethanol. RNA pellets were air dried for 5 
minutes, resuspended in RNase free water and flash frozen at -80°C. All solutions were made 
with DEPC treated water and all plastic ware was RNase-free. Absorbance @ 260/280nM was 
measured using a nano-drop spectrophotometer to determine RNA concentration and all samples 
were diluted to 30pg/pL. Quantitative real-time PCR was performed using the QuantiFast SYBR 
Green RT-PCR Kit (Qiagen) as per the manufacturer’s instructions. Briefly, 90pg of RNA was 
used for each reaction and reverse-transcription and PCR amplification were carried out in the 
same reaction using the QuantiFast thermo-sensitive enzyme mix. Reaction volumes were 25 pL, 
0.8pM primers were used, 5pL of Q Solution (Qiagen) replaced water in the TAp73 reactions 
and Ct values were measured after 35 cycles of a 2 step protocol of 30 second denaturation at 
95°C and 1 minute annealing and elongation at 55°C. All primer pairs were designed so that at 
least 1 covered an exon/exon boundary and the melting temperature was within 2 degrees of 
60°C. Relative expression was normalized to the expression of a P-actin control. Relative 
expression was represented as the average of three independent experiments. See Table 2.4 for a 
full description of primers and PCR conditions.
2 . 1 1  R e a l - t i m e  P C R
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Table 2,4 Description of PCR Conditions




5 ‘ CTTCGAGCACC 
TGTGGAGTT3’
Reverse
5 ‘ T GCT G AGC A A A 
TTGAACTGG3’
2x QuantiFast SYBR Green RT-PCR 
Mastermix -12.5 jaL 
Primer F (lOpM) -2pL 
Primer R(10pM) -2pL 
QuantiFast RT Mix -0.25 pL 
Template RNA (30ng/pL) -3.25pL 
Water -OpL 
Q solution -5pL
1) 50°C - 10 min
2) 90°C - 5 min
3) 95°C -10 sec
4) 60°C - 30 sec
Go to 3 for 40 cycles 
72°C - 10 min 
hold at 4°C 










2x QuantiFast SYBR Green RT-PCR 
Mastermix -12.5pL 
Primer F (lOpM) -2pL 
Primer R ( 1 OpM) -2pL 
QuantiFast RT Mix -0.25pL 
Template RNA (30ng/pL) -3.25pL 
Water -5pL
1) 50°C - 10 min
2) 90°C - 5 min
3) 95°C - 10 sec
4) 60°C - 30 sec
Go to 3 for 40 cycles 
72°C - 10 min 
hold at 4°C 







5 ’ ACATGCCGGAG 
CCGTTGTCG 3’
2x QuantiFast SYBR Green RT-PCR 
Mastermix -12.5pL 
Primer F (lOpM) -2pL 
Primer R ( 1 OpM) -2pL 
QuantiFast RT Mix -0.25pL 
Template RNA (3Ong/pL) -3.25pL 
Water -5pL
1) 50°C - 10 min
2) 90°C - 5 min
3) 95°C - 10 sec
4) 60°C - 30 sec
Go to 3 for 40 cycles 
72°C - 10 min 
hold at 4°C 
*Ct values approx 14
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Cell viability was quantitatively measured using the AlamarBlue cell viability reagent 
(Invitrogen). E2F1-reconstituted 3T3 were plated at a density of 5000 cells/100pL media per 
well in a 96 well dish. 24 hours after plating cells were treated with lOOuL of media containing 
lOpM etoposide. DMSO was used as vehicle control. 20 hours post treatment 8.7pL of 
AlamarBlue diluted in 21.3 pL of media was added to each well and after a 6 hour incubation 
fluorescence at a wavelength of 570nm was measured using a Wallac-Victor plate reader. Cell 
viability was represented as the average of three independent experiments.
Apoptosis was quantitatively measured using the Apo-ONE® Homogeneous Caspase-3/7 
Assay (Promega). Manufacturer’s instructions were followed. Briefly, cells were plated and 
treated as above. 24 hours post treatment with lOpM and 25pM etoposide cells were lysed using 
the 2X Apo-ONE®Caspase-3/7 Reagent and agitated on a plate shaker for 1 hour. Lysed 
supernatants were transferred to a white 96 well plate and the cleavage of the profluorescent 
caspase-3/7 substrate Z-DEVD-R110 was quantitated using an excitation wavelength of 499nm 
and measuring emittance at 521nm using a fluorescent plate reader (Biotek Synergy H4 Hybrid 
Reader). Fluorescence of the caspase-3/7 substrate was represented as the average of three 
independent experiments.
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3.1 Characterization of E2F1 antibodies
This work relied heavily on the interpretation of the results of E2F1 immunoprécipitation 
experiments and western blot analysis. Accordingly, we wanted to characterize the epitopes of 
the E2F1 antibodies we planned to utilize before investigating E2F1 complexes in response to 
DNA damage in our system. Two E2F1-specific (non phospho or acetylation-specific) antibodies 
were utilized throughout the course of this study; C20, a polyclonal antibody which recognizes 
an epitope in E2F1 ’s C-terminus, and KH20, a monoclonal antibody which recognizes an epitope 
in E2Fl’s N-terminus (both commercially available from Santa Cruz Biotechnology). Since 
E2F1 protein is phosphorylated at residues in both its N and C termini in response to DNA 
damage we wanted to confirm that C20 and KH20 did not recognize epitopes that were post- 
translationally modified and would therefore affect antibody recognition of E2F1 in response to 
DNA damage.
To map the epitopes of C20 and KH20 I performed a peptide spot assay. This assay 
consists of an array of 159 15-mer E2F1 peptides each with a one amino acid overlap with full 
coverage of the N-terminus (amino acids 1-90) and C-terminus (amino-acids 341-437) of human 
E2F1 (Table 2.2) spotted onto a nitrocellulose membrane. I incubated the membrane with either 
C20 or KH20 antibody and visualized antibody-peptide binding using a standard western blot 
procedure (see methods 2.3). The results of the peptide spot assay confirmed that both C20 and 
KH20’s epitopes lie outside the region of E2F1 that is post-translationally modified in response 
to DNA damage. The C20-E2F1 antibody reacted with peptides 147 to 159 (Figure 3.1 A). C20 is 
a polyclonal antibody so while no direct conclusions can be made about a minimal amino acid 
epitope for C20, I’ve determined it recognizes amino acids 411 to 437 of human E2F1. C20 had 
the highest affinity for peptide 159, which corresponds to the most C-terminal amino acids (422-
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Figure 3.1. Characterization of E2F1 antibodies.
A) Peptide spot membrane assayed for C20 epitope. Peptides with highest reactivity are indicated. 
Peptide identities are shown (left). The C20 epitope is shown in red. B) Peptide spot membrane 
assayed for KH20 epitope. Peptides with high reactivity are indicated. The KH20 epitope is shown in 
red. C) U20S were treated for 8 hours with lOOuM etoposide. Western blot analysis of nuclear extracts 
for E2F1 (KH20 or C20) and ATM-phosphorylated p53 (P-Serl5-p53). Lamin A/C served as a loading
control.
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437) of human E2F1 and so C20 likely contains antibodies most abundant or with the highest 
affinity towards E2Fl’s extreme C-terminus. The KH20-E2F1 antibody reacted with peptides 39 
to 51 and bound preferentially to peptide 45, which corresponds to N-terminal amino acids 45-59 
of E2F1. KH20 is a monoclonal antibody and so analysis of the sequence overlap of peptides 39 
to 51 revealed the KH20 minimal epitope to be a P-A-A motif corresponding to amino acids 51- 
53 of human E2F1 (Figure 3. IB). The post-translational modifications acquired by E2F1 in 
response to DNA damage lie at residues 31, 117, 120, 125, and 364, therefore C20 and KH20 are 
both ideal reagents for recognizing “total” E2F1, independent of DNA damage responsive post- 
translational modifications. E2F1 is also phosphorylated by CDKs at S/T-P motifs. Importantly, 
these S/T-P CDK phospho-acceptor sites lie outside both the sequence recognized by both KH20 
and C20. However, E2F1 is phosphorylated by p38/MAPK at serine 433 (Ivanova et al. 2009), 
inside the region recognized by C20. While it is possible that C20 could have lower affinity to 
p38/MAPK phosphorylated E2F1, it is known that this phosphorylation event occurs during 
keratinocyte differentiation and causes E2F1 to be excluded from the nucleus and degraded. As I 
collected only nuclear and not whole cell extracts during my experiments S433-phosphorylated 
E2F1 was not a consideration for my studies.
E2F1 is activated at the protein level in response to DNA damage. Treatment with agents 
that cause DNA double strand breaks, such as the topoisomerase inhibitor etoposide, cause an 
increase of E2F1 protein levels in cells with an intact DNA damage signaling pathway. 
Accordingly, both C20 and KH20 recognize an increase in endogenous E2F1 protein levels in 
response to DNA damage by western blot analysis (Figure 3.1C) further confirming their specific 
utility as antibodies which recognize “total” E2F1.
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3.2 Generation of a phospho-serine 31-E2F1 specific antibody
E2F1 is phosphorylated at serine-31 by the serine/threonine kinase Ataxia telangiectasia 
mutated (ATM) in response to double strand breaks (Lin et al. 2001). This phosphorylation event 
was the first DNA damage-dependent post-translational modification discovered for E2F1 yet 
there is no commercially available antibody targeted to this site. Therefore, before undertaking 
the study of endogenous DNA damage-responsive E2F1 post-translational modifications we 
wanted to create an antibody specific to this site. We contracted Covance Research Products Inc. 
to make a polyclonal antibody specific to this site. Rabbits were immunized with a KLH- 
conjugated 10 amino acid phospho-peptide surrounding the human E2F1 serine 31 sequence 
([H]-CKKKLD-pS-QIV-[NH2]). Serum was obtained and purified using a 2-step protocol of 
column chromatography. Phospho-serine 31 specific antibodies were first isolated by incubating 
serum with a phospho-serine 31 peptide-bound column and eluting the bound antibodies. Non- 
phospho and pan-specific E2F1 antibodies were removed from the eluate by incubation with an 
E2F1-peptide bound column and collecting the unbound eluate. Preliminary enzyme linked 
immunosorbent assays (ELISA) were performed to confirm the specificity of the purified 
immunized rabbit antisera to the injected phospho-peptide versus a non-phospho peptide control. 
When compared to the binding of a positive control antibody-peptide combination we saw that 
the purified immunized rabbit antisera recognized the injected phospho-peptide with higher 
affinity than a non-phospho-E2Fl peptide control (Figure 3.2 A). The positive result of the 
ELISA prompted us to collect all of the serum from the phospho-serine 31-E2F1 immunized 
rabbits in order to begin larger scale purifications and characterization of the reagent.
In order to test the specificity of our lab-made polyclonal phospho-serine-31 specific E2F1 
antibody I performed a variety of in vitro assays to test its ability to recognize ATM kinase
63
Figure 3.2. Generation of a phospho-serine 31-E2F1 specific antibody.
A) ELISA assay measuring the binding of the phospho-serine 31-E2F1 specific antibody to a phospho- 
serine-31-E2Fl peptide ( (P)-E2F1) compared to a non-phospho peptide (E2F1). The absorbance of the 
(+ cntl) sample depicts the binding of a matched antibody-epitope combination. B) In vitro kinase 
assay using Y-32P ATP. + indicates the kinase (CDK2 or ATM) or the protein substrate (GST-E2F1 or 
GST-S31A) added to the kinase reaction. IP indicates the antibody used to immunoprecipitate the 
protein substrate following the kinase reaction (RIgG indicates a rabbit species-specific negative 
control, P-Ser31 indicates the E2Fl-phospho-serine-31 specific antibody). C) Western blot analysis of 
in vitro kinase assay using the phospho-serine 31-E2F1 specific antibody. Western blot analysis using 
the KH20 antibody served as a loading control. Molecular weight of protein bands are indicated. D) 
U20S cells transfected with either wildtype E2F1 or E2F1-S31A were treated with lOOpM etoposide 
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phosphorylated E2F1 at serine 31.1 performed an in vitro kinase assay using y- P ATP and 
immunoprecipitated flag-ATM with recombinant E2F1 protein as a substrate and subjected the 
phosphorylated product to immunoprécipitation with the phospho-serine-31 specific E2F1 
antibody. Subsequent autoradiography of an SDS-PAGE gel that the immunoprecipitated sample 
was run on was performed to visualize the presence of ATM-phosphorylated E2F1. CDK2 
phosphorylated E2F1, ATM phosphorylated E2F1 with a serine 31 to alanine mutation and an 
IgG immunoprécipitation were used as negative controls (Figure 3.2B). The presence of a 
radioactive signal in lane 6 where wildtype E2F1 phosphorylated by ATM was 
immunoprecipitated with the phospho-serine-31 specific E2F1 antibody compared to the lack of 
a radioactive signal in lane 3 where the E2F1 with a serine 31 to alanine mutation was 
immunoprecipitated with the phospho-serine-31 specific E2F1 antibody demonstrated the ability 
of the antibody to recognize serine-31 phosphorylated E2F1 protein. A second in vitro kinase 
assay was performed in order to test the ability of the phospho-serine-31 specific E2F1 antibody 
to recognize serine-31 phosphorylated E2F1 protein by western blot. Wildtype recombinant 
E2F1 protein or a serine 31 to alanine mutant was subject to in vitro phosphorylation by 
immunoprecipitated flag-ATM or CDK2 (as a negative control). The samples were run on an 
SDS-PAGE gel and Western blot analysis was performed using the phospho-serine-31 specific 
E2F1 antibody and a “total” E2F1 antibody as a loading control (Figure 3.2C). This experiment 
demonstrated a lack of ability of the phospho-serine-31 specific E2F1 antibody to detect its 
epitope by western blot (see lack of signal in lane 1 and the presence of a non-specific 50 kDa 
signal in lane 3). The results gathered from the two in vitro kinases assays described led us to 
conclude that the phospho-serine-31 specific E2F1 antibody could recognize folded, non- 
denatured protein but not linearized protein as is present in a western blot.
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The applications we wished to utilize the phospho-serine-31 specific E2F1 antibody for 
were western blotting and immunoprécipitation of endogenous E2F1 protein from cells. To test 
the phospho-serine-31 specific E2F1 antibody’s efficacy in these two applications I performed 
western blots and immunoprécipitations from extracts of vehicle or etoposide treated U20S cells 
(human osteosarcoma cells which activate E2F1 appropriately in response to DNA damage) that 
were transfected to overexpress wildtype E2F1 or a serine 31 to alanine mutant of E2F1. The 
antibody demonstrated very poor specificity for E2F1 in western blot analysis (Figure 3.2D) and 
immunoprécipitation of endogenous or overexpressed E2F1 protein (data not shown). Due to the 
limited functionality of the phospho-serine-31 specific E2F1 antibody we decided we did not 
have a satisfactory reagent to study the endogenous phosphorylation of serine-31 in response to 
DNA damage.
3.3 DNA damage induces pRB-E2Fl complex formation
To investigate the regulation of endogenous pRB-E2Fl complex formation in response to 
DNA damage I performed pRB immunoprécipitations in U20S (human osteosarcoma) cells. 
U20S are widely utilized in the study of E2F1 activation and apoptosis (Martinez-Balbas et al. 
2000, O’Connor and Lu. 2000, Ianari etal. 2004, Markham et al. 2006, Martinez et al. 2009) as 
they respond appropriately to DNA double strand breaks by activating E2F1 (Figure 3.3A) and 
are wildtype for RB and p53 (Craig et al. 1998). Accordingly, I performed a control experiment 
demonstrating that the appropriate DNA damage responsive phosphorylation and acetylation of 
E2F1 also occurs in these cells (Figure 3.3B).
Once we had validated E2F1 was being appropriately activated and modified in our system 
we sought to investigate endogenous E2Fl/pRB complex formation in response to DNA damage.
6 6
67
Figure 3.3. E2F1 molecules can be fractionated into distinct populations following DNA 
damage.
A) U20S cells were treated with lOOpM etoposide (+) or DMSO (- untreated control) for 8 
hours after which nuclear extracts were analyzed by western blot analysis with the C20 antibody. 
P-actin served as a loading control. B) U20S were treated as above. Nuclear extracts were 
normalized for E2F1 levels and immunoprecipitated with the indicated antibodies (a-). 
Immunoprécipitation of E2F1 was analyzed by western blot using the KH20 antibody. C) U20S 
were treated as above. Nuclear extracts were immunoprecipitated with the indicated antibodies 
(a-). Endogenous pRB was quantitatively immunoprecipitated using the C15 antibody after 
which “free” E2F1 was immunoprecipitated from the pRB-IP supernatant (sup-a-C20). Western 
blot analysis using G3-245 (pRB) and KH20 (E2F1) was used to visualize pRB-bound or “free” 
E2F1 levels. D) Simplified version of quantitative immunoprécipitation experiment in (C) 
compared to a titration of recombinant E2F1 protein of known concentration (U20S were treated 
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In order to isolate total E2Fl/pRB complexes and “free” E2F1,1 treated cells with etoposide to 
induce DNA double strand breaks after which a “quantitative” pRB immunoprécipitation was 
performed to precipitate all of the pRB from U20S nuclear extracts in order to “quantitatively” 
isolate all of the pRB-E2Fl complexes present in the cells. This left a pRB-E2Fl complex- 
depleted extract, which I then immunoprecipitated for E2F1 and collected. Finally, I analyzed the 
immunoprecipitated complexes and complex-depleted extract for the presence of E2F1.1 
performed a western blot with an anti-pRB antibody to ensure pRB was “quantitatively” 
immunoprecipitated, and an anti-E2Fl antibody to make a direct comparison between the 
amount of E2F1 in complex with pRB and the amount of E2F1 not in complex with pRB 
following DNA damage. I consistently observed an increase in pRB/E2Fl complex formation in 
response to DNA damage (Figure 3.3C-compare lanes 4 and 7). Even when normalizing for the 
increase in E2F1 protein levels in response to DNA damage (see lanes 1 and 2) there is an 
obvious increase in abundance of pRB/E2Fl complexes when compared to vehicle treated 
control. In order to approximate the relative abundance of E2F1 in complex with pRB or “free” 
of pRB binding I repeated the pRB quantitative immunoprécipitation experiment under 
conditions of DNA damage only and ran an SDS-PAGE gel of the immunoprecipitated samples 
alongside a titration of purified recombinant E2F1 protein of known concentration and 
performed an anti-E2Fl western blot (all samples were run on the same gel and the nitrocellulose 
membrane was probed in 1 aliquot of antibody so that a direct comparison could be made) 
(Figure 3.3D). Strikingly, there is a 10-fold increase in the amount of E2F1 in complex with pRB 
than “free” when comparing E2F1 protein levels to the lng and lOng titration values. I also 
observed that DNA damage increases the abundance of pRB/E2Fl complexes in normal human 
lung fibroblasts (data not shown) indicating that this is not a cell type specific effect.
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3.4 DNA damage results in a CHK2 phosphorylated E2F1 complex with pRB
The observation that pRB/E2F 1 complexes increased in response to treatment with 
etoposide that resulted in apoptosis, was very interesting and we hypothesized that a DNA 
damage responsive post-translational modification intrinsic to the complex could be responsible 
for its formation. Both pRB and E2F1 acquire multiple post-translational modifications in 
response to DNA damage so we took a systematic approach to determining the post-translational 
modifications on each protein present in the complex beginning with the investigation of E2F1. 1 
performed a quantitative pRB immunoprécipitation (as described previously), but in this case 
normalized for total E2F1 in both the pRB bound and free E2F1 fractions. I utilized two 
commercially available antibodies specific to acetylated lysine residues and serine 364 
phosphorylated E2F1, respectively, for western blot analysis of the post-translational 
modifications present on E2F1 molecules in both the pRB bound and free E2F1 fractions (Figure 
3.4A). I observed the presence of acetylated E2F1 in both the free and pRB-bound E2F1 pools 
with a slight enrichment in the pRB-bound E2F1 pool. Strikingly, E2F1 phosphorylated on 
serine-364 was exclusively in complex with pRB. This experiment demonstrated two important 
findings. The first is that not all E2F1 is serine-364 phosphorylated in response to DNA damage, 
meaning distinct populations of E2F1 molecules exist following DNA damage. This distinction 
is important as the literature that describes DNA damage responsive post-translational 
modification of E2F1 does not do so in a quantitative way, therefore this study is the first to 
distinguish between modified populations of E2F1 molecules instead of assuming E2F1 
molecules are a homogeneous group containing all post-translational modifications in response 
to DNA damage. The second finding that resulted from the quantitative pRB
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Figure 3.4. DNA damage results in a CHK2 phosphorylated E2F1 complex with pRB.
A) U20S cells were treated with lOOpM etoposide for 8h after which nuclear extracts were 
collected and a pRB quantitative immunoprécipitation was performed. Samples were normalized 
for E2F1 levels and western blot analysis using G3-245 (pRB), an anti-P-Ser364-E2Fl specific 
antibody, an anti-Ac-lys specific antibody and KH20 was used to visualize levels of P-S364- 
E2F1 or Ac-E2F1 in complex with pRB. B) U20S were treated as above. Nuclear extracts were 
immunoprecipitated with the indicated antibodies (a-) and samples were normalized for E2F1 
levels. Western blot analysis using G3-245 (pRB), an anti-P-Ser364-E2Fl specific antibody and 
KE120 (E2F1) was used to visualize the indicated proteins.
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immunoprécipitation is that endogenous DNA damage responsive post-translational 
modifications on E2F1 may be selective for pRB binding.
Since it was apparent that serine-364 phosphorylated E2F1 was exclusively in complex 
with pRB and that only a subset of E2F1 molecules are serine-364 phosphorylated in response to 
DNA damage, we wanted to determine the relative contribution of pRB/phospho-S364-E2Fl 
complexes to the total population of pRB/E2Fl complexes in response to DNA damage. To do 
this I compared the amount of pRB that was immunoprecipitated using a phospho-S364-E2Fl 
specific antibody with an E2F1 antibody, normalized for the total amount of E2F1 that was 
immunoprecipitated by each and subsequently did a western blot for pRB (Figure 3.4B). In 
accordance with Figure 3.4A I observed that phospho-S364-E2Fl is found preferentially in 
complex with pRB compared to total E2F1 (compare lanes 3 and 4). Therefore, pRB/phospho- 
S364-E2F1 complexes are a major component of the total amount of pRB-bound E2F1 in 
response to DNA damage.
3.5 CHK2 phosphorylated E2F1 is not coincident with CHK2 phosphorylated pRB
Like E2F1, pRB is also regulated by post-translational modifications in response to DNA 
damage. Rb is methylated at lysines 810 and 873 by the Set7/9 methyltransferase, and at lysine 
860 by the SMYD2 methyltransferase (Munro et al. 2010, Saddic et al. 2010, Carr et al. 2011). 
pRB is acetylated at lysines 873 and 874 by p300 and phosphorylated at serine 612 by CHK2, 
both of which have been implicated as important in regulating apoptosis (Chan et al. 2001, Inoue 
et al. 2007). With the observation that DNA damage induced a complex between S364- 
phosphorylated E2F1 and pRB we sought to investigate whether S364-phosphorylated E2F1 
might be coincident with S612-phosphorylated pRB as they are both targets of CHK2 during the
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DNA damage response. To test this hypothesis I treated cells with etoposide and performed 
immunoprécipitations with a phospho-specific S364-E2F1 antibody and an E2F1 antibody and 
subsequently did a western blot with a phospho-specific antibody to S612-pRB (Figure 3.5). In 
comparing the amount of S612-phosphorylated pRB in complex with phospho-S364-E2Fl and 
total E2F1 I observed that S612-phosphorylated pRB is actually excluded from the phospho- 
S364-E2Fl/pRB complex (identified in Figure 3.4A). Importantly, this experiment demonstrated 
that phospho-S364-E2Fl is not simply existing in complex with pRB in response to DNA 
damage because E2F1 is being phosphorylated by CHK2 while bound to pRB. This indicates 
that serine-364 phosphorylation of E2F1 may actually serve as an active signaling mark in 
directing the communication of pRB and E2F1 in response to DNA damage.
3.6 CHK2 phosphorylated E2F1 forms a unique complex with hyperphosphorylated pRB 
that excludes other post-translational modifications
With the knowledge that phospho-S364-E2Fl/pRJB was a major pRB complex induced by 
DNA damage we sought to investigate the presence of pRB post-translational modifications in 
this complex. I performed immunoprécipitations for phospho-S364-E2Fl and total E2F1 and by 
western blot analysis with specific phosphorylation and acetylation antibodies against E2F1 and 
pRB we discovered that the P-S364-E2Fl/pRB complex is unique. Interestingly, S364- 
phosphorylated E2F1 binds to hyperphosphorylated (slower-migrating) pRB in response to DNA 
damage and this complex excludes other post-translational modifications on either protein 
(Figure 3.6A). Conversely, the total E2F1 antibody immunoprecipitated pRB/E2Fl complexes 
that are acetylated on both pRB and E2F1. The observations from this experiment have allowed 
us to conclude that discrete E2Fl-pRB complexes exist following DNA damage (Figure 3.6B).
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Figure 3.5. CHK2 phosphorylated E2F1 is not coincident with CHK2 phosphorylated pRB.
U20S cells were treated with lOOpM etoposide for 8h. Nuclear extracts were 
immunoprecipitated with the indicated antibodies (a-) and samples were normalized for E2F1 
levels. Western blot analysis was performed using an anti-P-Ser612-pRB specific antibody and 




Figure 3.6. CHK2 phosphorylated E2F1 forms a unique complex with 
hyperphosphorylated pRB that excludes other post-translational modifications.
A) U20S cells were treated with 1 OOpM etoposide for 8h. Nuclear extracts were immunoprecipitated 
with the indicated antibodies (a-) and samples were normalized for E2F1 levels. Western blot analysis 
using G3-245 (pRB), an anti-P-Ser364-E2Fl specific antibody, an anti-Ac-lys specific antibody and 
KH20 (E2F1) was used to assay the post-translational modifications present on both pRB and E2F1 in 
complex in response to DNA damage. ppRB=hyperphosphorylated, pRB=hypophosphorylated, 
determined by protein migration during SDS-PAGE. B) Model depicting post-translational 
modifications identified in distinct E2Fl/pRB complexes isolated in (A).
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We hypothesize that these discrete complexes can have differing functions, potentially a subset 
of pRB complexes exist to inhibit the cell cycle and a separate subset exist to regulate apoptosis 
in response to DNA damage and they are organized by their differing post-translational 
modifications.
3.7 A phosphomimetic construct of phospho serine-364 E2F1 does not induce assembly 
with pRB
With the observation that phospho serine-364 E2F1 was enriched with pRB we 
hypothesized that phosphorylation of S364 might actually induce complex assembly with pRB. 
To test this hypothesis I utilized a phosphomimetic E2F1 cDNA construct that contained a serine 
364 to glutamate substitution (HA-E2F1-364E) to mimic the negative charge incurred by E2F1 
at serine 364 in response to DNA damage by the addition of phosphate. To test if E2F1-364E had 
a greater binding ability than wildtype E2F1 for pRB I performed a GST-pulldown assay where I 
titrated increasing amounts of GST-pRB, starting at a very low concentration, and compared the 
ability of E2F1-364E and wildtype E2F1 to bind to GST-pRB (Figure 3.7A). I observed no 
difference in the ability of E2F1-364E or wildtype E2F1 to bind to GST-pRB. We hypothesized 
that this experiment had a negative result because it utilized a construct of pRB that was not 
modified during the DNA damage response, and potentially post-translational modifications on 
pRB (such as hyperphosphorylation) were also necessary for S364 phosphorylation of E2F1 to 
induce complex assembly with pRB. In order to control for this I performed a second experiment 
where I transfected U20S cells with HA-E2F1-364E or HA-E2F1-WT, treated with etoposide 
and immunoprecipitated E2Fl-pRB complexes with an anti-HA antibody (Figure 3.7B). Again, I 
observed no difference between the ability of E2F1-364E or wildtype E2F1 to bind to pRB.
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Figure 3.7. A phosphomimetic substitution of E2F1-S364 does not initiate complex formation with 
pRB.
A) HA-tagged constructs of wildtype E2F1 or an E2F1-S364 phosphomimetic (364E) were transfected 
into U20S cells. Nuclear extracts were incubated with increasing concentrations (0.025pg, 0.25pg, 1.0 
pg, 2pg) of GST-RB. E2F1 was visualized by western blot analysis using the KH20 antibody. B) HA- 
tagged constructs of wildtype E2F1 or E2F1-S364E phosphomimetic were transfected into C33A cells 
(pRB deficient). Transfected C33A nuclear extracts were incubated with lmg of endogenous U20S 
nuclear extracts following treatment with lOOpM etoposide for 8 hours (containing hyper and hypo- 
phosphorylated pRB). Complexes were immunoprecipitated through the E2F1 constructs’ HA-tag 
using the 12CA5 antibody. pRB and E2F1 were visualized by western blot analysis using the G3-245 
and KH20 antibodies, respectively.
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These two experiments indicate that phosphorylation of S364-E2F1 probably does not act as an 
assembly signal for E2F1 and pRB, however, these experiments utilized a phosphomimetic, and 
since the presence if a glutamate residue is not the same as the presence of phosphate we cannot 
rule this out completely.
3.8 Re-expression of E2F1 mutant constructs in E2fl-/~ 3T3 cells as a system to study the 
functional role of DNA damage responsive E2F1 post-translational modifications
Once we had identified a unique phospho-S364-E2Fl/ppRB complex induced by DNA 
damage we were interested in what its functional role might be. In order to determine the relative 
contribution of E2F1 S364 phosphorylation to its ability to induce apoptosis I utilized E2fl null 
mouse embryonic fibroblasts that were immortalized by continuous culture through a “3T3” 
protocol. The nature of a 3T3 protocol is such that cells acquire random mutations that render 
them immortal. Therefore, many 3T3 cell lines can begin to divide continuously by acquiring 
p53 mutations that cause the protein to be functionally inactive, rendering them immortal and 
p53 deficient. The E2fl null 3T3 cells I utilized were characterized as p53 deficient by observing 
a lack of p53 induction in response to DNA damage (Figure 3.8B). i stably reconstituted human 
cDNA constructs of wildtype E2F1, E2F1-TM (mutated for serine 31 and 364 and lysines 117, 
120 and 125), E2F1-DM (mutated for serine 31 and lysines 117, 120 and 125) and E2F1-S364A 
(mutated for serine 364) (Figure 3.8A) through retroviral infection into these E2fl null 3T3s, 
generating a genetic system in which it is possible to study the p53-independent apoptotic 
potential of E2F1 and its post-translational modifications. E2F1 is expressed at similar levels by 
all constructs in the reconstituted 3T3s (Figure 3.8C). As well, serine-364 phosphorylation of 
wildtype human E2F1 is intact in this system (Figure 3.8D).
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Figure 3.8. Re-expression of E2F1 mutant constructs in E2fl-/~ 3T3 as a system to study the 
functional role of DNA damage responsive E2F1 post-translational modifications.
A) Depiction of the amino-acid substitutions present in each E2F1-mutant construct re-expressed in 
E2fl-/- 3T3 (empty vector control not shown). B) Cells were treated with lOOpM etoposide for 8 hours 
(+) or DMSO (-) after which extracts were analyzed by western blot analysis using an anti-p53 
antibody. P-actin served as a loading control. C) The indicated E2F1-reconstituted E2fl-/- 3T3 cells 
were treated with 100pM etoposide for 8 hours (+) or DMSO (-) after which extracts were analyzed by 
western blot analysis using the C20 antibody. P-actin served as a loading control. D) The indicated 
E2F1-reconstituted E2fl-/- 3T3 were treated with 100pM etoposide for 8h after which nuclear extracts 
were immunoprecipitated with the indicated antibodies (a-) and immunoprecipitated E2F1 was 
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Before performing any functional apoptotic assays we wanted to validate there would be no 
major cell cycle differences upon the re-introduction of E2F1-mutant constructs into the E2fl-/- 
cells. This is important as cells that are arrested do not undergo apoptosis as robustly as cells 
actively proliferating. As E2F1 is a transcription factor that facilitates the Gl/S phase transition, 
we could not properly interpret any apoptotic activity of the E2F1 -mutant constructs if they had 
varying effects on cell proliferation. This is a control that has been commonly overlooked in the 
study of pRB and E2Fl’s role in inducing apoptosis, as the ectopic expression or loss of either 
protein can affect cell cycle and confound results of apoptosis assays. In order to determine 
whether the E2F1 mutants caused any cell cycle abnormalities I measured BrdU incorporation 
and analyzed the cell cycle profile of the E2F1-reconstituted 3T3s by flow cytometry. The cell 
cycle profile of the 3T3s showed no significant differences, regardless of the E2F1 mutant 
introduced (Figure 3.9A). Likewise, I performed a 6 day growth curve to compare cell 
proliferation in the E2F1 reconstituted cells and found there were no significant changes in cell 
proliferation (Figure 3.9B), although as expected the E2F1 reconstituted cells had a slight growth 
advantage when compared to the control cells that had been transduced with empty vector, 
indicative of E2Fl’s role in inducing S-phase progression during normal cell proliferation. The 
mutations introduced in E2F1 should only prevent DNA damage induced post-translational 
modifications and should not occur during normal cell proliferation, so the cell cycle analysis 
and proliferative results confirm that our system is appropriate to compare the apoptotic potential 
of the E2F1-mutant constructs following DNA damage.
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Figure 3.9. Control for cell cycle effects of E2Fl-mutant constructs.
A) Asynchronously growing cultures of the indicated E2F1 -reconstituted £2/7-/- 3T3 were pulse 
labeled with BrdU for 1 hour, processed for BrdU and PI staining and analyzed by flow 
cytometry. Results are graphed as the percent of total cells in G0/G1, S or G2/M (as calculated 
from indicated regions shown in red on a representative flow profile). Error bars indicate one 
standard deviation from the mean. B) Representative graph of a 6-day growth curve for the 
indicated E2F1-reconstituted 3T3. Total cell number was counted every 24 hours following 
plating for 6 days. Error bars indicate one standard deviation from the mean.
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3.9 Phospho-S364-E2Fl activates expression of pro-apoptotic E2F1 targets in response to 
DNA damage
E2F1 can directly transactivate the expression of many proapoptotic genes that contain E2F 
transcription factor binding motifs in their promoters and result in mitochondria-dependent 
apoptosis. E2F1 targets include the cytochrome-C binding protein APAF-1, caspases 3 and 7 (the 
key effectors of apoptosis), TAp73 which is a p53 family member and likely E2Fl’s most 
important apoptotic target and BH3-only proteins which inactivate Bcl-2 (Muller et al. 2001 and 
Irwin et al. 2000). In order to determine the relative contribution of E2F1 S364 phosphorylation 
to its ability to induce proapoptotic gene expression in response to DNA damage I performed 
gene expression analysis using quantitative RT-PCR on the reconstituted E2F1 null 3T3 
described above following treatment with etoposide. The TA (apoptosis inducing) isoform of the 
TAp73 gene was chosen as the descriptive proapoptotic target gene as it is an upstream indicator 
of apoptotic induction in the p53 deficient reconstituted E2F1 null 3T3.1 observed that the E2F1- 
S364A mutant was defective in activating TAp73 expression in response to etoposide treatment 
as compared to wildtype E2F1 (Figure 3.10A). Importantly, this effect was not due to the E2F1- 
S364A mutant being transcriptionally dead. Expression of the E2F1 cell cycle target cyclin A2 
was also measured in untreated cells and in response to DNA damage as a control for non- 
apoptotic transcriptional activation. Wildtype E2F1 and the E2F1-S364A mutant were 
indistinguishable in their ability to activate cyclin A2 expression (Figure 3.10B).
The observation that E2F1, that cannot be phosphorylated by CHK2, has a defect in 
activating apoptotic gene expression was very surprising as my biochemical data described thus 
far has strongly shown that phospho-S364-E2Fl is exclusively in complex with pRB. Since it is
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Figure 3.10. Phospho-S364-E2Fl activates expression of TAp73 in response to DNA 
Damage.
A) The indicated E2F1-reconstituted E2fl-/~ 3T3 were treated with 100pM etoposide or DMSO 
(untreated) for 6h. RNA was extracted and TAp73 induction was assayed by real-time RT-PCR. 
Results are normalized to the expression of P-actin and shown relative to the levels observed in 
untreated cells (set to 1). Bars represent the mean of three independent experiments. Error bars 
indicate one standard deviation from the mean. B) cyclin A2 relative expression and induction 
was assayed by real-time RT-PCR as in (A). Relative expression is shown relative to the levels 
observed in empty-vector transduced cells (set to 1). Fold induction is shown relative to the 
levels observed in untreated cells (set to 1).
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known that pRB is a transcriptional repressor of E2F1 in cycling cells we were intrigued at the 
idea that hyperphosphorylated pRB could be forming a transcriptionally active complex with 
E2F1 phosphorylated by CHK2. This result is also very interesting as it suggests that the DNA 
damage responsive ppRB/P-S364- E2F1 complex that I have identified is proapoptotic.
3.10 The phospho-S364-E2Fl/ppRB complex is proapoptotic
In order to determine if the DNA damage responsive ppRB/P-S364- E2F1 complex is 
proapoptotic I investigated both cell viability and caspase activity in the E2F1-reconstituted 3T3 
in response to DNA damage. In order to measure cell viability relative to wildtype E2F1 among 
the E2F1-mutant reconstituted 3T3 I treated cells with lOuM etoposide for 24hrs in the presence 
of the reagent AlamarBlue. AlamarBlue is a redox indicator that results in a fluorescent signal in 
response to a cell’s metabolic activity. In this way, AlamarBlue can only be used as an indicator 
of cell viability, and not apoptosis directly. As a first measure of the relative viability of the 
E2F1-mutant reconstituted 3T3s in response to DNA damage I observed that the wildtype E2F1 
reconstituted 3T3 cells were significantly less viable than all other E2F1-mutant reconstituted 
3T3s. As expected, the empty vector control reconstituted 3T3s were the most viable in response 
to DNA damage as they are deficient for both p53 and E2F1. An intermediate effect on viability 
was observed among the various E2F1-mutants whereby E2F1-TM was more viable than E2F1- 
DM and E2F1-S364A (Figure 3.11 A), indicating the additive effects that E2F1 post-translational 
modifications provide in the cellular response to DNA damage. Interestingly, the E2F1-S364A 
mutant reconstituted cells were significantly more viable than wildtype E2F1 in response to 
DNA damage.
The promising results of the AlamarBlue cell viability assay and the observation that
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Figure 3.11. Phospho-S364-E2Fl is proapoptotic.
A) The indicated E2F1 -reconstituted £2/7-/- 3T3 were treated with lOpM etoposide (or DMSO- 
untreated) for 24 hours. Cell viability was determined by incubation for 6 hours with the 
AlamarBlue cell viability reagent and measuring fluorescence at 570nm. Percent viability is 
represented as relative to the levels observed in empty-vector transduced cells (set to 100). Bars 
represent the mean of three independent experiments. Error bars indicate one standard deviation 
from the mean. B) The indicated E2F1-reconstituted E2fl-/- 3T3 were treated with 10pM and 
25pM etoposide or DMSO (untreated) for 24 hours. Apoptosis was quantitated by measuring 
absorbance at 521nm as an indicator of the cleavage of an added rhodamine linked caspase-3/7 
substrate. Bars represent the mean of three independent experiments. Error bars indicate one






E2F1-S364A was defective for induction of proapoptotic TAp73 prompted us to investigate 
phospho-S364-E2Fl’s apoptotic activity directly. In order to obtain a quantitative measure of 
apoptosis in the E2F1 reconstituted 3T3 I treated cells with 10pM etoposide for 24 hours (as 
before) after which cells were lysed and the cleavage of a fluorescent caspase-3/7 substrate was 
measured. In accordance with the trend seen in the measurements of cell viability in response to 
DNA damage, I observed a significant defect in the ability of the E2F1-S364A mutant to activate 
caspase activity in response to DNA damage (Figure 3.1 IB). Taken together, the results from 
two independent measures of cell death in response to DNA damage provide compelling 
evidence that the DNA damage dependent phosphorylation of E2F1 by CHK2 at serine-364 is 
proapoptotic. The biochemical data demonstrating that P-S364- E2F1 is only found in complex 
with pRB suggests a role for a DNA damage responsive ppRB/P-S364- E2F1 complex.
CHAPTER 4: DISCUSSION
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4.1 Summary of Findings
The E2F1 transcription factor has been studied for decades as the prototypical E2F family 
member that cooperates with pRB to control the Gl/S transition in animal cells. The ability of 
pRB to bind to E2F1 and block its transactivation domain to inhibit premature S-phase entry 
through transcriptional inhibition and the concomitant release of inhibition by 
hyperphosphorylation of pRB by mitogen stimulated cyclin dependent kinases is thought to be 
the main molecular interaction controlling a cell’s decision to replicate its DNA and proceed 
with mitosis (DeCaprio et al. 1989, Chellappan et al. 1991, Hiebert et al. 1992, reviewed in 
Dyson, N 1998). The identification of E2Fl’s unique role as an E2F family member that directly 
activates apoptosis in a DNA damage dependent manner added a layer of complexity to the 
seemingly established function of E2Fs as proto-oncogenes. As well, recent studies showing that 
E2F1 may interact with hyperphosphorylated pRB (Cecchini and Dick, 2010 and Ianari et al, 
2009) shifted the paradigm of our understanding of the biochemical regulation of pRB and E2F1 
interactions. The work presented here for the completion of my MSc thesis adds yet another 
layer of complexity in describing the intricate nature of pRB and E2F1 interactions.
I observed that DNA damage induced post-translational modification of both pRB and 
E2F1 can act as a “sorting” mechanism to create distinct populations of these protein complexes. 
I’ve characterized the presence of endogenous post-translational modifications on pRB and E2F1 
in at least 2 distinct complexes that form in response to DNA damage. Specifically, I found that 
E2F1 that is phosphorylated by CHK2 on serine-364 is found preferentially in complex with 
hyperphosphorylated pRB, and this ppRB/E2Fl-S364 complex is distinct from other pRB/E2Fl 
complexes that are acetylated. Likewise, I observed that acetylated E2F1 contributes to the 
proportion of “free” E2F1 but that serine-364 phosphorylated E2F1 constitutes a large proportion
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of the pRB/E2Fl complexes present in response to DNA damage and is never found free of pRB. 
While many studies have characterized the presence of pRB and E2F1 post-translational 
modifications in response to DNA damage separately (Lin et al. 2001, Stevens et al. 2003, Ianari 
et al. 2004, Pediconi et al. 2003, Chan et al. 2001, Markham et al. 2006, Inoue et al. 2007), this is 
the first to study the modifications on both proteins in the context of one another and to describe 
their contribution to the overall presence of pRB/E2Fl complexes and free E2F1 generated by 
DNA double strand breaks. As well, this study describes a proapoptotic role for E2F1-serine 364 
phosphorylation. Based on biochemical observations and functional data measuring TAp73 
expression and caspase cleavage in cells reconstituted for E2F1,1 describe a transcriptionally 
active proapoptotic pRB/E2Fl complex that exists in response to DNA damage and can be 
identified by serine-364 phosphorylated E2F1. These results provide mechanistic insight into the 
recent finding that hyperphosphorylated pRB can have proapoptotic activity in response to DNA 
damage (Ianari et al. 2009) and challenges our current understanding of the paradigm of pRB 
activation and inhibition mediated by hyperphosphorylation.
4.2 Formation of a DNA-damage dependent, transcriptionally active ppRB/E2Fl complex
The observation that E2F1 is predominantly in complex with pRB following etoposide 
treatment is in stark contrast to what we had expected to observe based on the work done 
previously in our lab that suggested DNA damage responsive post-translational modifications of 
E2F1 released it from pRB binding. We hypothesized that DNA damage promotes the release of 
E2F1 from repressive pRB complexes so that it may activate gene expression at proapoptotic 
targets and facilitate DNA repair. This hypothesis stems from years of research that indicates 
pRB and E2F1 form repressive complexes at E2F target genes because pRB blocks E2Fl’s
transactivation domain (Helin et al. 1993, Lee et al. 2002, Nielsen et al. 2001, Robertson et al. 
2000, Brehm et al. 1998, Magnaghi et al. 1998). Since much of E2Fl’s apoptotic ability is due to 
transcriptional activation of proapoptotic target genes (Muller et al. 2001 and Irwin et al. 2000) it 
seemed unlikely that “apoptotic” E2F1 could be in complex with pRB- a transcriptional 
repressor of E2F1. However, I’ve identified a complex between hyperphosphorylated pRB and 
serine-364 phosphorylated E2F1 that has proapoptotic activity in response to DNA damage 
which is mediated, at least in part, by transcriptional activation of TAp73. While the description 
of a transcriptionally active ppRB/E2Fl complex is novel, there is some evidence in the 
literature that this type of complex has been observed. For instance, a ChIP analysis identified 
pRB/E2Fl complexes at E2F target promoters in cells that were in S phase, a phase of the cell 
cycle where pRB should be hyperphosphorylated due to high CDK activity (Wells et al. 2003). 
As well, pRB was found at proapoptotic E2F target genes in cells treated with doxorubicin, and 
the presence of activating histone marks and DNA polymerase II was used to suggest that these 
pRB-bound proapoptotic E2F target genes were transcriptionally active (Ianari et al. 2009). In 
this second study, the authors went so far as to say they had identified a transcriptionally active 
complex between ppRB and E2F1 but provided no biochemical explanation as to how this could 
be possible. I believe that this thesis provides a mechanism by which hyperphosphorylated pRB 
may form a transcriptionally active complex with E2F1 in response to DNA damage.
A paper published previously in our lab demonstrates that the mechanism of E2F1 complex 
formation with hyperphosphorylated pRB is through a C-terminal E2F1-specific binding cleft in 
pRB called the “specific” site and the marked box domain of E2F1. The binding of pRB to E2F1 
through the specific interaction is thought to negatively regulate E2F1 dependent apoptosis while 
binding to E2F1 through the “general” site (which all E2Fs can bind) is thought to be responsible
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for cell cycle control during normal proliferation. While this idea seemingly conflicts with my 
hypothesis that hyperphosphorylated RB is forming a proapoptotic complex with phospho-S364- 
E2F1 in response to DNA damage, I hypothesize that S364 phosphorylation near E2Fl’s marked 
box domain acts as a regulatory switch to activate the apoptotic ability of the ppRB/E2Fl 
complex in response to genotoxic stress (Figure 4.1), potentially by relieving pRB inhibition of 
the E2F1 transactivation domain. In this way CHK2 phosphorylation of E2F1 would function as 
an activating mark, relieving pRJB inhibition of E2F1 transcriptional activity at proapoptotic 
E2F1 target genes in response to DNA damage that had previously been occupied by repressive 
pRB/E2Fl complexes. In order to test this hypothesis I’ve performed experiments in which a 
pRB mammalian expression construct or an pRB construct that contains mutations in pRB’s 
general site that abrogates E2F1 binding in the pocket domain and shifts binding to the C- 
terminal “specific” site (pRB-AG) was titrated into E2Flwt or E2F1-S364A transfected E2fl-/- 
cells along with a TAp73-luciferase reporter and treated with etoposide. TAp73-luciferase 
activation was measured in order to assay the contribution of pRB’s “general” and “specific” 
binding clefts in regulating E2F1 dependent apoptosis during cell proliferation and in response to 
the DNA damage dependent phosphorylation of serine-364 (data not shown). Preliminary 
observations indicate that wildtype E2Fl/pRB complexes formed through pRB’s specific site 
activate the TAp73 promoter and this effect seems to be lost if complexes are formed through 
pRB’s specific site using an E2F1-S364A mutant. This data indicates the mechanism of forming 
transcriptionally active proapoptotic ppRB/E2Fl complexes in response to DNA damage could 
be mediated through the pRB’s specific binding cleft and activated by E2F1-S364 




Figure 4.1. Model of pRB mediated regulation of E2F1 dependent apoptosis.
During normal cell proliferation hypophosphorylated pRB regulates the Gl/S transition by binding to 
E2F1 in the general E2F binding cleft. E2F1 dependent apoptosis is regulated by inhibitory binding to 
hyperphosphorylated pRB in the E2F1-specific binding cleft. In response to genotoxic stress, the 
proapoptotic activity of the ppRB-E2Fl “specific” complex is activated by CHK2 phosphorylation of 
E2F1 on serine 364. Serine 364 phosphorylation relieves inhibition of the E2F1 transactivation domain 
and converts a repressive complex into a transcriptionally active complex. A second, distinct 
pRB/E2Fl complex exists that is acetylated in response to DNA damage. Acetylation recruits the 
histone acetyltransferase PCAF and transcription is activated at E2F1 target genes. E2F1 free of pRB 
binding contains other post-translational modifications and may activate apoptosis by transcriptional 
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4.3 Conservation of E2F1-serine-364
Interestingly, E2Fl’s C-terminal CHK2 phospho-acceptor site is not conserved in mouse. 
While there have not been studies to investigate whether E2F1 is actually phosphorylated by 
CHK2 in mouse, I observe that murine cells expressing a human E2F1 cDNA will phosphorylate 
E2F1 at serine-364 in response to DNA double strand breaks (Figure 3.8D). This result is 
interesting for two reasons. Firstly, mouse cells can phosphorylate serine-364 of human E2F1 in 
response to DNA damage, presumably using endogenously available CHK2. This increases 
E2Fl’s ability to induce apoptosis and transcriptionally activate TAp73 when compared to 
mouse cells expressing a mutant construct of E2F1 that cannot be phosphorylated at serine 364 
because of an alanine substitution. It is as though all of the machinery is in place in mouse cells 
to utilize E2Fl’s C-terminal CHK2 phospho-acceptor site if given the opportunity. This indicates 
that the gain in apoptotic activity seen with wildtype human E2F1 may be intrinsic to the 
formation of an activated ppRB/E2Fl complex alone and not involving the recruitment of a 
transcriptional coactivator that has evolved to participate in this complex. Secondly, the fact that 
E2Fl’s C-terminal CHK2 phospho-acceptor site is not conserved in mouse is interesting as it 
suggests one explanation for the observation that human cells are more sensitive to DNA 
damaging agents than mouse cells (Humbert et al. 1999, Suzuki et al. 1992, Hornsby, 2003).
It has been previously demonstrated that serine 364 phosphorylation of E2F1 stabilizes the 
protein and increases the accumulation of cells with subGl DNA content in response to DNA 
damage (Stevens et al. 2003). My work has demonstrated that serine 364 phosphorylation of 
E2F1 is required for E2Fl’s maximal transcriptional activation of TAp73 and induction of 
apoptosis in response to DNA damage. The experiments described in chapters 3.8-3.10 
demonstrated that all E2F1 DNA damage responsive post-translational modifications (serine 31
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phosphorylation, lysine 117, 120 and 125 acetylation and serine 364 phosphorylation) provide a 
gain of activity for TAp73 activation and apoptotic induction. Consequently, I propose that 
serine 364 phosphorylation of E2F1, while important for the activation of TAp73 and apoptosis 
in response to DNA damage, acts more like a fine tuning mechanism than an all or none response 
to DNA damage. It is conceivable that human cells evolved E2Fl’s C-terminal CHK2 phospho- 
acceptor site relatively late in evolution by a simple substitution in the E2F1 gene, and this 
change persisted as it provides organisms a selective advantage by allowing cells to activate 
apoptosis more efficiently in response to genotoxic stress.
4.4 Perspectives
The observations I have presented in this thesis provide a mechanistic basis for the 
understanding of pRB and E2FI interactions in response to DNA damage. Interestingly, it 
appears that multiple distinct pRB/E2Fl complexes are formed between differentially modified 
versions of these proteins in response to DNA damage (Figure 3.6 A). While I have determined 
that the function of the ppRB/E2Fl phospho-serine-364 complex is to accentuate a cells’ 
apoptotic response to DNA damage, the function of the acetylated complex of pRB/E2Fl that I 
purified remains unknown. While I observed that E2F1 acetylation is important for TAp73 
transcription and apoptotic induction in response to DNA damage, I cannot directly attribute this 
to the activity of the acetylated pRB/E2Fl complex as I observed that acetylated E2F1 also exists 
free of pRB binding following DNA damage. It is possible that the acetylated complex of 
pRB/E2Fl does in fact contribute to DNA damage mediated apoptosis. This hypothesis is in line 
with another that proposes that pRB, E2F1 and PCAF form a transcriptionally active complex at 
proapoptotic E2F1 target genes in response to DNA damage (Ianari et al. 2009). It is also
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possible that the apoptotic activity of acetylated E2F1 can be fully attributed to “free” E2F1, as 
we had previously thought (Figure 1.6).
I have determined that multiple distinct pRB/E2Fl complexes are formed between 
differentially modified versions of these proteins in response to DNA damage. However, this 
work does not include a description of the complete set of post-translational modifications of 
pRB and E2F1 in response to DNA damage. Mass spectrometry analysis of protein complexes 
purified by immunoprécipitation using E2Fl-phospho-serine 364-specific and acetyl-lysine 
specific antibodies could provide useful information about the complete spectrum of post- 
translational modifications present in distinct pRB/E2Fl complexes. As well, this experiment 
would reveal the coactivators or co-repressors found in complex with pRB and E2F1 molecules 
containing these post-translational modifications. Discovering the full identity of the protein 
complexes in which post-translationally modified pRB and E2F1 participate would allow for a 
better understanding of their functional role. For example, the finding that pRB méthylation is 
important for binding to HP1 provides evidence that the functional role of pRB méthylation is to 
facilitate transcriptional repression (Munro et al. 2010). Based on our current knowledge of 
pRB/E2Fl interactions and post-translational modification in response to DNA damage, I 
propose a model to explain the proapoptotic activity of pRB/E2F 1 complexes in response to 
genotoxic stress (Figure 4.1). In this model, it is not the binding of pRB that regulates E2F1 
dependent apoptosis but the combination of post-translational modifications present on each 
protein that dictates the activity of the complex. In this way, the apoptotic activity of pRB/E2Fl 
complexes is activated by CHK2 phosphorylation or PCAF acetylation in response to DNA 
damage. Post-translational modifications could dictate protein complex activity in two ways. 
Firstly, post-translational modifications could activate pRB/E2Fl complexes through “de-
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repression”. In this scenario, CHK2 phosphorylation of E2F1 in repressive pRB/E2Fl complexes 
could relieve pRB’s inhibition of the E2F1 transactivation domain and allow for expression of 
E2F1 target genes. Secondly, post-translational modifications could facilitate the recruitment of 
transcriptional coactivators or corepressors. In this scenario, the acetylated pRB/E2Fl complex 
recruits PCAF, a histone acetyltransferase that binds to acetylated proteins through a conserved 
bromodomain (Zheng et al. 2008), to facilitate expression of E2F1 target genes.
Dissecting the functional role of each post-translational modification placed on pRB and 
E2F1 in response to DNA damage is crucial from a human disease standpoint. As most cancer 
cells evolve inactivating mutations in the tumor suppressor p53, it is known that malignant cells 
respond to genotoxic therapies using the E2Fl-TAp73 axis of mitochondrial apoptosis (reviewed 
in Polager and Ginsberg, 2009). As well, while most cancers are known to contain pRB pathway 
mutations, these are usually due to p i6 deficiency, which results in the maintenance of 
hyperphosphorylated pRB in tumors (reviewed in Sherr and McCormick, 2002 and Knudsen and 
Knudsen 2008). In other words, pRB and E2F1 expression is maintained in many cancers. The 
intricate involvement of pRB and E2F1 in DNA damage dependent apoptosis (such as is induced 
by the administration of chemotherapeutic agents in human cancer) warrants a thorough 
understanding of the regulation of pRB and E2F1 function during a cell’s response to genotoxic 
stress. The work presented in this thesis increases our understanding of the functional role of 
endogenous pRB and E2F1 in response to DNA damage through the undertaking of a detailed 
investigation of pRB and E2F1 DNA damage responsive post-translational modifications.
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